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ABSTRACT
LYNETTE S. PHILLIPS: Breast Ductal Carcinoma in Situ (DCIS): Reproductive and
Hormonal Risk Factors and Reliability of Histologic Diagnoses
(Under the direction of Robert C. Millikan)
Ductal carcinoma in situ (DCIS) accounts for nearly one-fifth of all newly
diagnosed breast cancers in the United States. It comprises a heterogeneous collection of
histopathologic characteristics, but reproducibility among pathologists is unknown due to
lack of a uniform classification system. Recent data suggests that medium or low-grade
(non-comedo type) DCIS differs from high-grade (comedo type) with regard to biological
mechanisms, pathology, and risk factors and therefore may not require the same
treatment intensity given to more aggressive forms of the disease.
Aims of this dissertation were to investigate: 1) agreement by pathologists on
histopathologic diagnoses for DCIS subtypes, 2) which of the major diagnostic
components contribute most often to each subtype diagnosis, and 3) whether known
reproductive and hormonal risk factors for invasive breast cancer are risk factors for
DCIS, and if associations differ between comedo and non-comedo DCIS. The
dissertation utilized data from the Carolina Breast Cancer Study (CBCS), a population-
based case-control study of in situ and invasive breast cancer.
When clinical pathologists rated DCIS histopathologic specimens, agreement was
moderate for overall diagnosis and fair for the two most common cellular components
characteristic of the disease, pattern of necrosis and maximum nuclear diameter. The
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most advanced categories for each component were associated with comedo type DCIS,
while no uniformity existed for non-comedo type.
Case-control analyses examined reproductive and hormonal risk factors for
invasive breast cancer and both DCIS subtypes. In general, those decreasing estrogen
exposure, such as parity, lactation, older age at menarche and younger age at menopause
were inversely associated with disease, whereas factors causing increased estrogen
exposure such as oral contraceptive use and postmenopausal hormone replacement
therapy use showed increased associations with one or more breast cancer types. Results
for comedo type DCIS were similar to invasive breast cancer and differed from non-
comedo type for some risk factors. Although the lack of strong diagnostic reliability for
DCIS subtypes suggests a potential for error in the risk factor analyses, these results
support the division of DCIS cases by subtype for clinical and research purposes and
reinforce the need for a universal DCIS classification system.
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CHAPTER I: BACKGROUND AND LITERATURE REVIEW
Introduction
Carcinoma in situ (CIS) of the breast is a broad classification for malignant cells
confined to the epithelium of the breast lobules (lobular carcinoma in situ, or LCIS) or
ducts (ductal carcinoma in situ, or DCIS). LCIS accounts for approximately 14% of all
CIS cases in the United States [1], is often multicentric and/or bilateral [2], and is usually
detected in conjunction with other benign or malignant diseases rather than on its own.
LCIS has been considered a marker of invasive breast cancer risk rather than a direct
precursor to malignancy [3, 4], although recent evidence suggests risk of invasive disease
after LCIS is similar to risk of invasive cancer after a DCIS diagnosis [5].
Over 85% of CIS cases in the U.S. are DCIS. DCIS is usually detected by
screening mammogram, is sometimes multicentric but infrequently bilateral, and is
considered a direct precursor to invasive breast cancer in some cases [4]. DCIS is further
defined by histopathologic characteristics, although no universal classification system for
DCIS exists. Comedo-type or high-grade DCIS makes up only 20% of all U.S. DCIS
cases but is likely to develop into invasive disease if left untreated [1]. The remaining
80% of DCIS cases consist of noncomedo-type or intermediate or low-grade DCIS. At
the present, the severity of the latter lesions is unknown.
2Breast Carcinoma in Situ Pathology
LCIS is the more severe component of lobular neoplasia (LN), with atypical
lobular hyperplasia (ALH) representing similar but less well-developed lesions.
Pathologic characteristics of DCIS are numerous and varied, due to the heterogeneity of
the disease. Until recently, pathologists used architectural growth patterns to classify
DCIS. Many pathologists now categorize DCIS into two subtypes based on patterns of
necrosis, nuclear grade, and presence or absence of calcification. Those having “at least
one duct in the breast…filled and expanded by large, markedly atypical cells
and…abundant central luminal necrosis”[6] are considered comedo-type DCIS, while all
other forms are classified as noncomedo. These include cribriform, micropapillary,
clinging, and solid types [6]. Nuclear grade refers to the comparison of size and shape,
chromatin distribution, and mitoses of tumor nuclei versus those of normal cells [7].
While nuclear grade, architectural growth pattern, and tumor size all vary in
DCIS, it is not clear how much impact the various pathologic characteristics have on
determining severity of the disease. In addition, very small foci of invasive breast cancer
may be present with DCIS. Known as DCIS with microinvasion, this outcome has
important clinical and possibly etiologic implications. Microinvasion is often associated
with higher histologic grade [8]; specifically, 66-80% of the DCIS in cases with
microinvasion are comedo type [9].
Classification of LCIS is relatively straightforward, but the more heterogeneous
DCIS lesions do not easily lend themselves to a simple classification system.
Pathologists in the United States and Europe have been working to develop one DCIS
classification system that can be used universally with sufficient reliability and that
3prioritizes the elements with the most clinical impact. The four most prevalent
classification systems are listed in Table A.1. They differ based on how lesions are
categorized and which components are most important for categorization. Nuclear grade
and necrosis are features included in all systems, but their definitions and importance
vary.
Studies in recent years have explored reproducibility, accuracy, and ability to
predict disease progression and outcome among these systems and other combinations of
DCIS pathology. The studies can be divided into three types: those examining reliability
without regard to classification system, those investigating reliability for one specific CIS
classification system, and those comparing reliability for multiple classification systems.
Some studies included breast lesions other than CIS, such as benign breast lesions,
various types of hyperplasia, and invasive disease. Table A.2 summarizes the pertinent
details of previous reliability studies of benign breast disease and CIS pathology. They
vary in number of raters from two to 466 and in cases from 12 to 180. Four studies used
ratios (or percentages) to measure agreement, while the majority used the kappa statistic.
Most reported only inter-rater statistics, but two also examined diagnostic accuracy [10,
11], and one measured intra-rater reliability [12].
Raters differentiated among DCIS subtypes in only two of these studies [13, 14].
Three divided hyperplasia into subtypes [15-17], two studied CIS characteristics such as
nuclear pleomorphism and mitoses, and two delineated between high, intermediate, and
low grade DCIS. Three studies provided training sets of slides to the participating
pathologists before the study was conducted [16, 18, 19], and three others gave the raters
information on particular rating systems before they participated in the study[10, 20, 21].
4A uniform CIS classification system would be useful in selecting treatment that
involves the least amount of invasiveness and trauma (both physical and emotional) while
preventing recurrence. A number of studies have looked at predictors for DCIS
recurrence or development of invasive disease after initial CIS diagnosis using current
DCIS classification systems. Gupta et al (1997), Badve et al (1998), Denoux et al (2001),
and Bijker et al (2001) all found significant correlation between the Van Nuys system and
risk of recurrence of either DCIS or invasive breast cancer [22-26]. Gupta et al also
showed an association between the Holland system and concurrent grade of invasive
carcinoma, and Badve et al indicated good ability of that classification system to predict
local DCIS recurrence when cell polarization was not included in the definition.
Additional studies that did not look at classification systems have shown that
specific histologic features of DCIS are associated with poor prognostic grades of
invasive carcinoma both concomitantly and in recurrences after initial DCIS diagnosis.
Specifically, degree of epithelial proliferation in benign breast disease [27], poorly
differentiated nuclei [26, 28], high nuclear grade [29-31], and comedo necrosis [29, 32-
35] have all been found to correlate with local DCIS recurrence, risk of invasive cancer,
and/or grade of concurrent invasive disease. In fact, in many of these studies, type of
treatment had less impact on disease-free survival or mortality than subtype of DCIS. All
of this information supports the theory that DCIS subtypes may differ enough from each
other to be considered separate diseases clinically.
5Epidemiology of Breast Carcinoma in Situ
Epidemiologic data on LCIS is fairly scarce. Autopsy series indicate prevalence
of LCIS up to 4%, and Detroit SEER incidence rates for 1987-88 were 2.8 per 100,000
for LCIS [2]. Average age of diagnosis appears to be in the 40s, and diagnoses are
primarily among premenopausal women [2]. A recent Danish study found rate of
recurrence of invasive carcinomas, DCIS, or LCIS plus DCIS after LCIS diagnosis to be
17% [36], and Sasson et al discovered 5% of their invasive carcinoma population to have
concurrent LCIS [3].
Treatment for LCIS often consists of the diagnostic biopsy only with follow-up
observation and yearly mammograms [2, 37]. However, in high-risk patients local
excision or mastectomy may be used. In addition, a regimen of Tamoxifen may be
prescribed to decrease risk of subsequent breast cancers [37]. Because LCIS does not
directly lead to death, mortality rates deal with subsequent invasive disease risk and
death. Of 14 studies examining breast cancer deaths after LCIS diagnosis and treatment,
mortality rates ranged from 0.8% to 16% for those treated with local excision and 0% to
3% for those who had mastectomies [2].
Incidence rates for DCIS have been increasing ever since the National Cancer
Institute’s Surveillance, Epidemiology and End Results (SEER) program began recording
such data in 1973, when the age-adjusted annual rates were 2.3 per 100,000 females [38].
By 1992, that figure had jumped to 15.8 per 100,000 [39]. The most dramatic increases
have occurred since 1983, with a 17.5% annual increase in rates between 1983 and 1992
compared to increases of 3.9% annually from 1973 to 1983 [39]. Separate studies in
Detroit [40], Connecticut [41], Vaud, Switzerland [42], and Florence, Italy [43] have
6shown that most of this increase is due to the introduction of screening mammography in
the early 1980s and subsequent increasing use in women over 40, even though screening
programs targeted women 50 and over.
The SEER data has also been used to examine race and age differences in DCIS
rates. Age-adjusted incidence rates for black women have been slightly lower than for
whites nearly every year since 1973 but follow the same trends. Specifically, age-
adjusted incidence rates in 1983 were 3.7 per 100,000 for whites and 3.8 for blacks,
increasing to 15.8 and 14.4 per 100,000 respectively in 1992 [39]. Among white women,
12.1% of all newly diagnosed breast cancer cases in 1992 were DCIS, as were 12.5%
among black women [44].
In comparison, age-adjusted incidence rates for invasive breast cancer in 1992
were 131.8 per 100,000 overall, 135.6 per 100,000 for white women and 123.2 per
100,000 for black women according to SEER data [45]. As of 2002, the most current
year for which data is available, those rates are 133.8, 139.4, and 120.2 per 100,000,
respectively [45].
As with LCIS, risk of subsequent invasive breast cancer and death from that
disease is the most important concern with ductal carcinoma in situ, since DCIS does not
directly cause death. Recent analyses from SEER data of breast cancer deaths among
women diagnosed with DCIS between 1984 and 1989 showed five- and ten-year
standardized mortality ratios (SMRs) of 1.6 and 1.9 respectively, compared with women
in the general population [46]. In contrast, those same data for lesions diagnosed
between 1978 and 1983 (prior to common use of screening mammography) were 3.1 and
3.4 [46].
7Twenty-year survival rates for women diagnosed with in situ breast cancer
between 1973 and 1980 in the Breast Cancer Detection Demonstration Project (BCDDP)
were 78.5 observed (absolute) and 97.2 adjusted for deaths from other causes (relative)
[47]. For invasive cases, these rates were 59.3 observed and 78.2 adjusted [47]. In this
study, over 280,000 volunteer women in the U.S. were given annual breast cancer
screening for five years, with a 96% follow-up rate after 20 years. While these data most
likely are not representative of all U.S. women, they do provide the longest follow-up
data to date and a method for comparing survival of those with DCIS and those who
developed invasive breast cancer in the same study.
Recurrence of DCIS is also a concern. In one recent study, follow-up of over
1000 patients diagnosed with DCIS at Memorial Sloan-Kettering Cancer Center between
1978 and 1990 showed 157 subsequent recurrences for which follow-up data was
available [29]. Univariate analyses of 6-year actuarial local recurrence rates showed that
younger age (<40 yrs.), comedo histologic subtype, higher nuclear grade, and positive
surgical margins were significantly associated with higher recurrence rates. However,
positive margin status was the only statistically significant predictor in multivariate
analyses. Other studies found associations of higher recurrence with comedo necrosis
[34, 48-53], positive margin status [52, 54], and high nuclear grade [34, 48, 53].
While incidence data for invasive breast cancer come from SEER data, mortality
rates for invasive disease are obtained from death certificates and computed at the
National Center for Health Statistics. For 2003, those rates per 100,000 persons were
25.8 for all females, 25.3 for whites, and 34.3 for blacks [45]. The study of breast cancer
mortality among those originally diagnosed with DCIS also used SEER data to examine
8breast cancer deaths among women originally diagnosed with invasive disease [46].
Divided by severity of disease at diagnosis, five- and ten-year SMRs for 1978-83 were
17.8 and 16.8 for locally-invasive lesions, 64.3 and 55.5 for regionally invasive, and
290.4 and 254.2 for distant disease, respectively. For the period of 1984-89, these ratios
decreased somewhat to 11.8 and 11.4 for local disease, 50.5 and 45.1 for regional
invasion, and 258.3 and 232.8 for distant.
Current five-year relative survival rates for invasive breast cancer are 86%
overall. Computed by race, those rates are 87% for white women and 72% for black
women [55]. However, survival by stage of disease varies dramatically, with 96.4% of
women with localized disease surviving to five years, 77.7% with regional metastasis,
and 21.1% for those with distant metastasis [56]. Twenty-year adjusted survival rates in
the BCDDP study by stage were reported as 86.8 for stage I, 75.4 for stage IIa, 71.7 for
stage IIb, 70.1 for stage IIc, 59.6 for stage IId, and 40.3 for stage III [47].
Endogenous Estrogen and Breast Cancer
Endogenous estrogen stimulates breast cell growth and differentiation.
Specifically, it binds to and activates estrogen receptors in the cell nucleus [57].
Experiments using human mammary cell lines and animal models provide biological and
molecular evidence that lifetime events affecting estrogen levels, such as pregnancy,
lactation, and length of time between menarche and menopause, cause sufficient cellular
changes in the breast to affect breast cancer risk [58]. Epidemiologic studies support
these findings for invasive breast cancer. Specifically, early age at first pregnancy,
increasing number of pregnancies, long duration of lactation [59], late menarche, and
9early menopause, all of which decrease lifetime estrogen exposure, decrease breast
cancer risk. In addition, exogenous hormone use via hormone replacement therapy
(HRT) or oral contraceptives (OC) have shown increased breast cancer risk in some
studies [60-62]. Assuming that CIS is a precursor to invasive disease, these factors
should affect risk for CIS as well.
Carcinoma in Situ and Reproductive Events
Table A.3 summarizes previously published studies of CIS reproductive risk
factors. Results that were imprecise or showed weak or no association are not included in
the table, unless they helped describe trends. Of the nine studies, six are population-
based case-control designs, one is cross-sectional, and two are prospective cohorts.
Nearly all of the populations studied consist of mostly White and/or Hispanic
participants, and the Swedish study by Lambe, et al was the only one conducted on a non-
U.S. population.
In general, any full-term births and births at young age (<20 years) were inversely
associated with CIS whereas nulliparity and age at first full-term birth >30 years were
positively associated with CIS in these studies. The two studies that included lactation
suggest a positive association of CIS with lactation for more than 2 months [63, 64], but
others found no association between CIS and lactation.
Wohlfahrt et al (2004) conducted the only other study to examine reproductive
risk factors for comedo and non-comedo DCIS. Their analyses were limited to parity and
age at first full-term birth and found an association between comedo DCIS and age at
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first birth of 25 or higher. Neither parity nor age at first full-term birth were associated
with noncomedo DCIS.
Exogenous Hormones and Carcinoma in Situ
Overall, the most consistent risk factors for CIS in these studies were having a
first-degree relative with a history of breast cancer, previous benign breast disease or
biopsy, and ever use of hormone replacement therapy. Two of the studies conducted
separate analyses for pre- and postmenopausal subjects[65-67], and one studied only
premenopausal women[66]. Two of the studies limited their analyses to those who were
postmenopausal in order to study HRT as a risk factor[68, 69]. The remainder analyzed
all ages together.
Kerlikowske et al [67] and Gapstur et al [70] focused only on DCIS cases, while
the rest combined DCIS and LCIS in their analyses. Only the study by Claus et al [71]
performed separate analyses for LCIS cases. Previous breast biopsy was the only
variable found to be associated with LCIS, but that is most likely a result of high
correlation between diagnostic method and diagnosis.
The prospective cohort study of CIS by Schairer et al [68], which looked at
hormonal risk factors in postmenopausal women, studied 150 case subjects and found an
association between any in situ breast cancer and ever-use of HRT (estrogen and
progestin) as well as duration of use less than four years and current use. For estrogen-
only replacement therapy (ERT), an association was found for current use of >10 years
and a trend with increasing duration of use. For both total duration and past duration of
estrogen-only use, only the 10-14 year category was statistically significant. While this
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study included a number of variables in the regression model, including age, age at
menopause and type, history of benign breast disease, family history of breast cancer,
education, and parity, main effects were not presented. In addition, mean follow-up was
only 6.4 years, and more time might be necessary to examine hormonal influences on CIS
risk.
Longnecker et al [65] found age at menarche >14 years, previous benign breast
disease, family history of mother or sister with breast cancer, and first full-term birth
between the ages of 20 and 29 years to be risk factors for premenopausal women. The
results for parity were not significant, but nulliparity could not be addressed because the
authors did not include zero pregnancies as a category for this variable among
premenopausal women. No explanation for this choice was given. For postmenopausal
women in this population, previous benign breast disease, first degree relative with a
breast cancer history, age at menopause of 55 years or more, and ever use of HRT were
associated with DCIS and increasing number of full-term births beyond one showed an
inverse association with DCIS. Age at menarche, BMI, age at first full-term birth, and
ever use of ERT were all non-significant.
In the premenopausal population of Weiss et al, mother with history of breast
cancer, previous breast biopsy, African-American race, and nulliparity were all
associated with CIS, while some college education was inversely associated. Non-
significant factors measured include age at menarche, number of full-term births, age at
first full-term birth, interval since last birth, and alcohol use. Numbers of CIS studied by
type were mentioned (156 DCIS, 46 LCIS), but separate analyses were not conducted.
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Kerlikowske et al [67] found similar results with family history of breast cancer in
at least one relative associated with DCIS in premenopausal participants. In addition,
increasing age per 10-year increment was associated with DCIS in this study. Early
menarche (<12 years old), previous breast surgery and palpable mass associated with
diagnosis were all non-significant. Among postmenopausal women, only nulliparity or
older age at first birth (>30 years) were associated with DCIS. Hysterectomy was not
significant, and hormone replacement therapy was not included as a variable in this
study.
The study by Henrich et al [69] was much smaller (32 in situ cases) and had a
much lower participation rate (54%) than the other studies. Again, only postmenopausal
hormonal risk factors were studied, and no association was found with either ERT or
HRT use and CIS, even when categorized by recentness of use, type of estrogen, or
duration of use. This study analyzed invasive and in situ breast cancer cases together, as
well as invasive cases separately, but only reported ERT use results for in situ cases
alone. ERT use and estrogen use alone were associated with IBC (OR 1.93, 95% CI
1.06-3.94; and OR 2.22, 95% CI 1.18-4.17 respectively) but not with in situ and invasive
cancer cases combined. Most likely, this was due to the small sample size.
Gapstur et al [70] conducted the other prospective cohort that, like the Schairer
study, focused on hormone replacement therapy among postmenopausal women with
DCIS or invasive breast cancer. Although HRT was not found to be associated with
DCIS, it was not separated by type as performed by Schairer et al. However, other
potential risk factors were analyzed and 30 years or higher age at first birth and family
history of breast cancer were found to be positively associated with DCIS.
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The three largest and most recent studies, conducted in Sweden[72],
Wisconsin[73], and Connecticut[71], all combined pre- and postmenopausal women in
their analyses. Lambe et al [72] focused only on reproductive history risk factors, and
there is no indication what potential confounders, if any, were controlled for in the
analysis. They found parity to be protective, and increasing number of full-term births
resulted in an increased protective effect (p for trend 0.005). Also, increasing age at first
birth was associated with CIS (p for trend 0.05), but none of the risk estimates for the
individual age categories were statistically significant. Although this study contained a
very large number of subjects, its narrow focus and sparse analyses limit its usefulness
for increasing knowledge about CIS risk factors.
A more robust CIS risk factor study was the one conducted by Trentham-Dietz et
al [73]. Response rates for both cases and controls were very good (85% and 90%
respectively). Data was obtained through telephone interview, with a small reliability
study of the questionnaire conducted after 6-12 months showing high reproducibility.
While they did not consider pre- and postmenopausal women separately in their analyses,
they did adjust for a variety of confounders. In addition, this study conducted case-case
analyses to compare exposure variables for in situ versus invasive cancer. Risk factors
found in this study included family history of breast cancer, benign breast disease for
which a biopsy had been conducted, and postmenopausal hormone use. Many other
potential risk factors were examined, and parity, education, and BMI were all non-
significant.
As mentioned above, Claus et al [71] included a large number of CIS cases and
therefore were able to perform separate analyses for DCIS and LCIS. Specifically, there
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were 875 DCIS cases and 123 LCIS subjects in the analyses. Results for LCIS were
similar to those for DCIS, although the only statistically significant risk factor for LCIS
was previous breast biopsy (adjusted OR 4.15 [95% CI 2.34-7.35]), and linear trend for
age at menopause (1.07 [95% CI 1.01-1.12]). Telephone interviews were used in this
study as well, but there was no mention of reliability of the questionnaire.
Even though numbers of DCIS research studies have increased in recent years,
few explored risk factors or histopathologic characteristics of subtypes. Those
distinguishing between comedo and non-comedo types included only a portion of the
hormone-related exposures associated with invasive disease, and histopathologic
reliability studies have not examined how DCIS diagnoses are made. The purpose of this
dissertation is to:
1. Quantify inter-observer reliability on histopathologic diagnoses for DCIS cases
among pathologists in clinical practice,
2. Examine agreement for histopathologic diagnostic components and how they
contribute to the overall diagnosis,
3. Determine whether reproductive and hormonal risk factors for IBC are associated
with DCIS in the CBCS population, and
4. Divide DCIS cases by histologic subtype and compare risk factors to invasive
cancer.
CHAPTER II: STUDY DESIGN AND METHODS
The Carolina Breast Cancer Study
Overview of study
All data for these analyses came from the Carolina Breast Cancer Study (CBCS),
a population-based case-control study of women aged 20-74 residing in 24 contiguous
counties of North Carolina [74]. These counties were chosen to maximize African-
American and rural population representation and minimize identification and
recruitment problems due to population mobility. Phase I of the study included cases
diagnosed between May 1, 1993 and September 30, 1995, and was limited to invasive
cases. Phase II encompasses those diagnosed between 1996 and 2001 and includes both
invasive and in situ cases.
Among both cases and controls, randomized recruitment [75] was used to identify
nearly equivalent numbers of African-American and white women as well as of women
younger than age 50 and age 50 or older. Invasive cases were over-sampled for African-
Americans and younger women (20-49 years). CIS cases were identified through the
North Carolina Central Cancer Registry and were required to be first diagnoses of in situ
breast cancer with less than two millimeters of microinvasion. All eligible CIS cases
were included, with no over sampling on race or age. Controls were selected from a
Department of Motor Vehicle (DMV) list for women under age 65 and from a Health
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Care Finance Administration (HCFA) list for those aged 65-74. Controls were
frequency-matched to the cases on race and five-year age group.
Data Collection
Permission to contact potential cases was obtained from their physician. A letter
was sent to eligible cases and controls, followed by a telephone call if possible. If the
woman did not want to participate in the full interview, she was asked to complete a mini
questionnaire over the phone. A total of 705 CIS cases, 940 CIS controls, 2704 invasive
cases and 3600 invasive controls were identified for contact. Reasons for non-
participation after identification included inability to locate the person, ineligibility,
patient or physician refusal, or death. Numbers of subjects in each of these categories
and contact, cooperation, and response rates are shown in Table A.5. Contact,
cooperation, and response rates were computed as follows: the contact rate is those able
to be contacted divided by the total identified; the cooperation rate is the number who
completed the full interview or mini questionnaire divided by those eligible to be
contacted; and the response rate is the number who completed the interview or mini
questionnaire divided by those eligible to be selected (total identified minus ineligible
and deceased).
Upon agreement to participate in the full interview, trained nurse-interviewers
scheduled in-person interviews, usually at the woman’s home. At the interview, the
nurse administered a detailed questionnaire and took height, weight, waist, and hip
measurements. In addition, 30ccs of blood were drawn, and written permission to
acquire medical records and paraffin-embedded tumor blocks was obtained from cases.
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The tumor blocks were used to make 10 hematoxylin and eosin (H&E) stained slides to
be used for histopathologic and molecular research.
Slides from CBCS cases diagnosed at the University of North Carolina (UNC)
Hospitals were used to conduct a pathology study that examined inter-observer reliability
of overall diagnosis and histopathologic components of DCIS. Pathologists from
hospitals supplying tumor blocks and/or slides to the CBCS were recruited via a letter
requesting volunteer participation in the reliability study and follow-up phone calls. Of
30 pathologists contacted, five agreed to participate in this study.
Only UNC cases were used for the reliability study due to ease of access to tumor
blocks and pathology reports and so that IRB approval would only be required from one
institution. Fifty-six of the CBCS DCIS cases were from UNC. Slides from 53
contained sufficient quality and size for inclusion in this reliability study. One slide per
case was used, and the 53 slides were divided into four slide batches consisting of 13-14
slides each. Each pathologist received one batch at a time along with a one-page data
entry form for each slide. When the current batch and completed forms were returned,
the next batch was shipped.
For each slide, pathologists indicated the quality of the slide preparation and
selected one of seven categories for overall diagnosis: comedo DCIS, non-comedo
DCIS, lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH), other in situ
proliferation, no proliferative lesion present, and unable to determine. If the pathologist
assigned comedo or non-comedo DCIS as the overall diagnosis, the following additional
information concerning components of the DCIS diagnosis was requested: pattern of
necrosis (central/comedo-type, punctate/individual cell, and absent (no necrosis)),
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maximum nuclear diameter (1.5 to 2 times, 2.1 to 2.5 times, or >2.5 times the diameter of
a red blood cell), architectural growth pattern, nuclear chromatin pattern, and
characteristics of nucleoli.
The pathologists were instructed to follow criteria and procedures used in their
current practice and did not receive any special training prior to participating in the study,
because we were interested in measuring clinical practice procedures. Pathologists also
indicated whether they used an ocular micrometer to assess nuclear diameter for each
slide. Only pattern of necrosis and maximum nuclear diameter data were analyzed for
this study, because these components are included in the major classification systems and
have been found to best predict clinical outcome [76].
Description of Study Population
When both phases of the invasive study were complete, data was available for
1808 invasive cases and 1564 controls. The CIS portion of the CBCS consisted of 508
cases, of which 446 were DCIS only, and 458 controls, identified and interviewed
between 1996 and 2001. Table A.6 illustrates the main demographic characteristics for
all invasive and DCIS participants. Age was computed from self-reported birth date.
Because very few participants were American Indian/Eskimo, Asian or Pacific Islander,
or Other (n=13 for DCIS, n=53 for invasive), they were combined with Whites, resulting
in two race categories: African-American and non African-American.
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Data Analysis
Ductal Carcinoma in Situ and Invasive Risk Factors
The main outcome variables were ductal carcinoma in situ, which included all
cases of pure DCIS, and invasive breast cancer. Initial diagnosis was assigned by the
referring physician and verified by a pathologist employed by the CBCS using pathology
reports and H&E stained slides. Fewer than two percent of the DCIS cases were
reclassified as invasive based on the CBCS pathologist’s evaluation. Main hormonal and
reproductive risk variables included parity, age at first full-term pregnancy, lactation, oral
contraceptive (OC) use and duration of use, hormone replacement therapy (HRT) use and
duration of use, age at menopause, and age at menarche.
Univariate analyses were used to describe exposure and outcome variable
distributions and identify missing values and possible outliers. Odds ratios and 95
percent confidence intervals were computed using unconditional logistic regression. In
addition to analyses for all DCIS cases combined, univariate and multivariate analyses
were conducted for DCIS cases stratified on histopathologic subtype (comedo vs. non-
comedo). All regression models contained an offset term to adjust for age and race
frequency matching. All evaluations of potential effect measure modification and
confounding were conducted on the in situ data only, in order to obtain the model with
the best fit for that data. The resulting model was used for the invasive data in order to
make direct comparisons between in situ and invasive model estimates.
In order to determine the least biased estimates of the outcome-exposure
relationship, a methodology using backward elimination was utilized to evaluate effect
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measure modification and confounding. Potential effect measure modifiers were
identified a priori and evaluated by comparing models including an interaction term and
the main outcome and exposure effects with models containing the main effects only.
These included age, race, education, income, and first-degree family history of breast
cancer. Using the likelihood ratio test (LRT), a cut point of =0.10 determined whether
or not the interaction term remained in the final model [77]. After this process had been
performed for each of the main exposure covariates, no effect measure modification was
found.
In addition to the main covariates, potential confounders included age, race,
education, income, alcohol use, smoking, first-degree family history of breast cancer, and
body mass index (BMI). If addition of the covariate to the model resulted in a 10
percent or larger change in stratum-specific regression coefficient (), that variable was
considered a confounder and remained in the final model. Only age and race created
sufficient changes and were controlled for in the final model.
Inter-observer Reliability
The number of times a specific classification was chosen by each observer for
overall diagnosis, pattern of necrosis, and maximum nuclear diameter was determined.
In addition, number of cases for which the same classification category was selected by
all five (100% agreement), four out of five (80% agreement), or three out of five (60%
agreement) observers was determined, along with the number of cases for which there
was “no majority agreement” (zero to two out of five) for a category.
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Because no gold standard exists for CIS histopathologic diagnoses, a consensus
rating was determined for each question based on the classification chosen by at least
three pathologists for each case. If there was no majority classification, the consensus
rating was missing for that case. Although this method is inherently biased toward
agreement, since the individual ratings make up the consensus, it enables direct
comparison among ratings for each slide. Cohen’s kappa statistic (), a measure of
agreement beyond chance, was used to assess inter-observer reliability for each of the
categories for each rater compared to each of the other raters and to the consensus [78].
Kappa is zero if the observed agreement is consistent with a random assignment of
classifications among observers, and 1.0 if there is perfect agreement.
The kappa statistic does not rely on knowledge of actual diagnosis, making it
more informative than simple percent agreement [79]. However, a prevalence effect can
occur with kappa when the proportion of agreement for one category differs from that of
another [80]. A large difference in proportions (the prevalence index) results in a lower
kappa, with greater attenuation occurring for larger kappa values [80]. In addition, the
difference in proportions of disagreements (the bias index) results in a higher kappa than
when there is little or no bias, and the bias effect has more impact when kappa is small
[80]. Prevalence and bias indices were calculated for all kappa statistics in this study.
Simple pair-wise kappa statistics were computed for components with nominal
categories, i.e. overall diagnosis and pattern of necrosis. Weighted kappas (which give
more weight to cases in which disagreement varies by only one category versus two or
more) were calculated for the ordinal component maximum nuclear diameter. For each
component, an overall or “global” kappa was calculated that is a weighted average of all
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ratings for each component as well as for every category of overall diagnosis, pattern of
necrosis, and maximum nuclear diameter using a SAS® macro
(http://ftp.sas.com/techsup/download/stat/magree.html). The resulting statistic estimates
agreement among categories rather than individual observers and has been called a
summary kappa in other reliability studies [12, 81, 82].
CHAPTER III: INTER-OBSERVER RELIABILITY OF DUCTAL CARCINOMA IN
SITU HISTOPATHOLOGY IN CLINICAL PRACTICE
Abstract
Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease with no
single histopathologic classification system. It is unclear which features pathologists use
to categorize DCIS in clinical practice, and the consistency of categorization among
pathologists is unknown. Five pathologists from separate North Carolina hospitals rated
53 slides of DCIS on overall classification (comedo or non-comedo type DCIS), pattern
of necrosis (central/comedo-type, punctate/individual cell, or absent) and maximum
nuclear diameter to determine inter-observer reliability using the kappa () statistic.
Agreement on overall diagnosis was moderate (=0.48, 95% CI=0.41-0.55), while
reliability was fair for necrosis pattern (=0.35, 95% CI=0.30-0.41) and maximum
nuclear diameter (=0.22, 95% CI=0.16-0.28). These results indicate the inconsistency
in DCIS classification and add to the growing evidence that a universal classification
system is needed to ensure accurate, reliable DCIS diagnoses.
Introduction
As U.S. incidence rates of ductal carcinoma in situ (DCIS) of the breast have
increased with the increase in mammographic screening in the early 1980s, pathologists
have struggled to define and categorize the disease. DCIS are malignant breast tumors
that are confined to the lactiferous ducts, without stromal invasion across the basement
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membrane. Pathologic characteristics of DCIS are heterogeneous, with variation by
nuclear grade, amount and type of necrosis, and growth pattern. When combined, these
characteristics determine the grade of DCIS and its likelihood to develop into invasive
disease. However, pathologic classification of DCIS is not uniform, and final diagnoses
may differ depending upon the classification system used [51, 83-86]. Variation in the
methods, reliability and validity of pathologic diagnostic schemes used in actual practice
settings may influence the reliability of DCIS subtype classifications, which in turn may
affect treatment decisions and the design and conduct of DCIS research studies.
Previous studies of inter-observer reliability of breast histopathology included few
DCIS cases [11, 13, 15, 16, 21, 81, 87] or compared reliability using one specific
classification system rather than reproducing actual clinical practice procedures [10, 12,
18-20, 88]. However, the heterogeneous nature of DCIS requires that a sufficient number
of cases be included in a reliability study to capture the variety of pathologic
characteristics that comprise a DCIS diagnosis.
Knowing which components lead a pathologist to a specific diagnosis and how
they compare with other pathologists’ ratings of the same components would clarify the
diagnostic process, independent of the specific classification scheme used. For instance,
comparing agreement on specific components with agreement on overall diagnosis would
clarify which components are most important for consistency in determining DCIS
subtype diagnoses across pathologists. This information could simplify diagnostic
criteria and lead to greater consensus and ideally to the development of a universal
classification system. In addition, it could identify areas where additional training is
needed.
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The current study was conducted to (1) examine how well pathologists from
university and community hospital settings agree on overall histopathologic diagnoses for
DCIS cases, particularly for the two most common subgroups, comedo (high-grade)
DCIS and non-comedo (low-grade) DCIS; (2) determine which diagnostic components
have the highest and lowest agreement among pathologists; and (3) explore which of the
major diagnostic components contribute most often to the diagnosis of comedo versus
non-comedo DCIS subtypes.
Methods
Specimen Selection
Carcinoma in situ specimens were selected from those already obtained for
participants in the Carolina Breast Cancer Study (CBCS), a population-based case-
control study of in situ and invasive breast cancer among women aged 20 to 74 residing
in 24 North Carolina counties [74]. New carcinoma in situ (CIS) cases diagnosed
between 1996 and 2001 were identified by rapid ascertainment in conjunction with the
North Carolina Central Cancer Registry [89]. Only cases diagnosed at the University of
North Carolina (UNC) were included in this study. A formalin-fixed, paraffin-embedded
tumor block was provided by UNC Hospitals for each CIS case, from which ten sections
were cut and hematoxylin and eosin (H&E) stained. For uniformity, the tenth H&E
stained slide of each tumor block was used for this reliability study; the other nine were
used to confirm the diagnosis or were designated for other research studies. Of 56 total
UNC cases included in the CBCS, 53 were of sufficient quality and size for inclusion in
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this reliability study. Potential raters for this study were 30 pathologists who had
supplied tumor blocks and/or slides to the CBCS.
Pathologist Recruitment
Pathologists were recruited via a letter requesting volunteer participation in the
reliability study. Five North Carolina pathologists from five different hospitals agreed to
participate in this study, including three from large urban teaching hospitals with cancer
centers and two from smaller suburban community-based hospitals. The pathologists
were instructed to follow criteria and procedures used in their current practice and did not
receive any special training prior to participating in the study.
Study Procedures
The 53 case slides were divided into four batches consisting of 13-14 slides each.
Each pathologist received one batch at a time along with a one-page data entry form for
each slide. For each slide, pathologists indicated the quality of the slide preparation and
selected one of seven categories for overall diagnosis: comedo DCIS, non-comedo
DCIS, lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH), other in situ
proliferation, no proliferative lesion present, and unable to determine. If more than one
lesion type was present, pathologists chose one at their discretion. Additional
information concerning components of the DCIS diagnosis was requested for cases
assigned comedo or non-comedo DCIS as the overall diagnosis, including pattern of
necrosis (central/comedo-type, punctate/individual cell, and absent (no necrosis)),
maximum nuclear diameter (1.5 to 2 times, 2.1 to 2.5 times, or >2.5 times the diameter of
a red blood cell), architectural growth pattern, nuclear chromatin pattern, and
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characteristics of nucleoli. Pathologists also indicated whether they used an ocular
micrometer to assess nuclear diameter for each slide. Only pattern of necrosis and
maximum nuclear diameter were analyzed for this study, because these components are
included in the major classification systems and have been found to best predict clinical
outcome [76].
Statistical Methods
Data were double entered into a database, error checked, and imported into the
SAS statistical program (version 8.0, SAS Institute, Cary, NC) for statistical analyses.
The number of times a specific classification was chosen by each observer for overall
diagnosis, pattern of necrosis, and maximum nuclear diameter was determined. In
addition, the number of cases for which the same classification category was selected by
all five (100% agreement), four out of five (80% agreement), or three out of five (60%
agreement) observers, or where there was “no majority agreement” was determined.
Because no gold standard exists for CIS histopathologic diagnoses, a consensus
rating was determined based on the classification chosen by at least three pathologists for
each case. If there was no majority classification, the consensus rating was missing for
that case. Although this method is inherently biased toward agreement, since the
individual ratings make up the consensus, it enables direct comparison among ratings for
each slide. It is possible to determine whether some raters agree with each other more
consistently than others and if raters are more likely to choose one category versus
another compared with the other raters. A consensus value has been used in other
reliability studies when no gold standard was available [90, 91].
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Cohen’s kappa statistic (), a measure of agreement beyond chance, was used to
assess inter-observer reliability for overall diagnosis, pattern of necrosis, and maximum
nuclear diameter [78]. Kappa is zero if the observed agreement is consistent with a
random assignment of classifications among observers, and 1.0 if there is perfect
agreement. The following table specifies qualitative ranges that can be used for
subjective interpretation of agreement measured by kappa [92]:
 Statistic Level of Agreement
<0.20 Poor
0.21-0.40 Fair
0.41-0.60 Moderate
0.61-0.80 Good/Substantial
0.81-1.00 Very Good/Almost Perfect
The kappa statistic does not rely on knowledge of actual diagnosis, making it
more informative than simple percent agreement [79]. However, a prevalence effect can
occur with kappa when the proportion of agreement for one category differs from that of
another [80]. Using the example 2x2 table shown below, the prevalence index is
computed by dividing the absolute value of the difference between frequencies in the
agreement cells (‘a’ and ‘d’) by the total number of ratings (n=a+b+c+d):
Observer 1
Diagnosis 1 Diagnosis 2
Diagnosis 1 a bObserver 2
Diagnosis 2 c d
Total a+c b+d
Prevalence index = a-d
n
A large prevalence index results in a lower kappa, with greater attenuation occurring for
larger kappa values [80]. In addition, a bias effect occurs when there is a difference in
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proportions of disagreements. The bias index is the absolute value of the difference
between frequencies in the disagreement cells (‘b’ and ‘c’) divided by the total number of
ratings (n):
Bias index = b-c
n
Kappa tends to increase with increasing bias, and the bias effect has more impact when
kappa is small [80]. Prevalence and bias indices were calculated for all kappa statistics in
this study.
Simple pair-wise kappa statistics were computed for components with nominal
categories, i.e. overall diagnosis and pattern of necrosis, and weighted kappas (which
give more weight to cases in which disagreement varies by only one category versus two
or more) were calculated for maximum nuclear diameter, which is an ordinal component.
For each component, an overall or “global” kappa was calculated that is a weighted
average of all ratings for each component as well as for every category of overall
diagnosis, pattern of necrosis, and maximum nuclear diameter using a SAS® macro
(http://ftp.sas.com/techsup/download/stat/magree.html). The resulting statistic estimates
agreement among categories rather than individual observers. Other reliability studies
have used this statistic to describe agreement among all pathologists within the study,
sometimes calling it a summary kappa [12, 81, 82].
Results
Frequencies and Percent Agreement
All five pathologists rated the same H&E stained section from each of the 53
individual cases, resulting in 265 total ratings. Each pathologist classified at least 85% of
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the cases as either comedo or non-comedo DCIS, for a total of 236 ratings (Table 3.1);
however, the classification of individual cases as comedo or non-comedo DCIS differed
among the observers. Pathologists B and C classified more cases as comedo type than
any other, D and E chose non-comedo most frequently, and A selected the two categories
with equal frequency. The most common necrosis pattern assigned to comedo and non-
comedo cases was the central/comedo-type necrosis pattern (Table 3.2). Maximum
nuclear diameter classifications varied the most among observers, especially for the small
(1.5 to 2) and large (>2.5) categories (Table 3.3). Three observers (A, C, and E) used the
ocular micrometer to measure maximum nuclear diameter for at least 95% of the cases,
one (D) used it for just over half the cases, and one observer (B) only used it for three
cases (data not shown). Micrometer use did not affect results for maximum nuclear
diameter.
Consensus agreement, represented by three or more pathologists concurring, was
obtained for 52 of the 53 cases for overall diagnosis (Table 3.4). Complete agreement by
all five observers on overall diagnosis occurred for 20 of the 53 cases. Of these, nine
were diagnosed as comedo, nine as non-comedo, and two as other. For pattern of
necrosis, complete agreement occurred for 22 cases, of which all but one was comedo-
type. All observers agreed on only six cases for maximum nuclear diameter, with five of
those in the large category.
Of the 236 ratings with an overall diagnosis of DCIS, six were missing data for
pattern of necrosis, maximum nuclear diameter, or both. For the 230 observations with
complete data, necrosis pattern and maximum nuclear diameter categories were
compared between observations classified as comedo and non-comedo DCIS subtypes
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(Figure 3.1). Over 95 percent of the slides rated as comedo-type DCIS were classified as
central/comedo-type necrosis, and almost 75 percent were also classified as large
maximum nuclear diameter. In contrast, necrosis and nuclear size characteristics of
slides classified as non-comedo DCIS were more heterogeneous, with 42%, 20%, and
38% classified as central/comedo, punctate or no necrosis (respectively), and 29%, 45%
and 27% classified as small, medium and large maximum nuclear diameter. The most
common joint classification was central/comedo-type necrosis and medium nuclear
diameter (19%), followed by no necrosis and medium nuclear diameter (18%).
Inter-observer Reliability
Prevalence and bias indices were low for all comparisons and therefore did not
greatly influence the magnitude of kappa statistics. Inter-observer reliability analyses for
each diagnostic component generated four pair-wise kappa statistics that were averaged
for each observer (Table 3.5). Mean inter-observer kappa statistics were highest for
overall diagnosis, with values for three pathologists indicating moderate reliability and
two showing fair reliability when compared with the other four observers; however,
individual pair-wise kappas for overall diagnosis ranged from 0.21 to 0.66. Inter-
observer reliability was lowest for maximum nuclear diameter, with average kappa
statistics indicating only fair agreement for all observers.
Results for each observer also were compared with consensus values based on
simple or weighted kappa statistics as appropriate (Table 3.5). In general, kappa statistics
for agreement with the consensus value for each characteristic were higher than pair-wise
(inter-observer) kappas. With inter-observer comparisons, agreement was highest for
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overall diagnosis and lowest for maximum nuclear diameter. For the consensus kappas,
agreement was highest for overall diagnosis but nearly equal for the other components.
Global kappa estimates for all observers combined indicated that agreement was
highest for overall diagnosis (=0.48) and lowest for maximum nuclear diameter
(=0.22) (Table 3.6). Reliability results were similar for the three categories of DCIS
overall diagnosis but varied among necrosis categories (=0.57 for central/comedo type
and =0.18 for punctate/individual call) and nuclear diameter categories (=0.33, 0.16
and 0.15 for large, medium and small maximum diameter, respectively).
Discussion
The incidence of ductal carcinoma in situ (DCIS) of the breast has increased
dramatically over the past 15 years due to increased use of routine mammography
screening. Lesions defined as DCIS vary with regard to cytonuclear grade, necrosis,
architecture, growth pattern, and progression to invasive carcinoma. Proposed DCIS
classification systems emphasize different histopathologic characteristics, with Bellamy
et al focusing on architecture [93], Holland et al on cytological grade [83], Poller et al on
necrosis [51], and the Van Nuys Prognostic Index (VNPI) on a combination of nuclear
grade and necrosis [86].
In 1997, an international conference convened to establish consensus guidelines
for evaluation of DCIS pathology, including the classification of DCIS and identification
of features affecting prognosis in DCIS patients [94]. The committee recommended that
specific items be included in a DCIS pathology report, but no single classification system
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was endorsed due to insufficient evidence that one system could be replicated easily and
reliably.
Since then, reliability studies have examined which of the many DCIS pathology
rating systems are most repeatable among pathologists, both with training [18, 19, 82]
and without [12, 88]. Each study included different numbers of observers and cases, and
agreement was higher if pathologists were trained before the study. For the VNPI,
arguably the most popular system, results from four different studies ranged from a high
of =0.66 (for pathologists who received a tutorial on the diagnostic criteria plus
supporting written information and accompanying photographic aids) to a low of =0.26
(for pathologists given written information on the system only) [12, 18]. Similar results
were reported for the Holland system (=0.57 for observers given a tutorial and written
material, =0.37 for those receiving only a written description) [18, 88], and for the
system developed by Lagios (=0.46 with a training set of slides and written criteria,
=0.26 with only written information) [12, 19]. These results suggest that specific
instruction and written aids are necessary for pathologists to achieve more than moderate
agreement on DCIS histopathology.
The results of the current study indicate that without specific rating guidelines,
pathologists in a variety of clinical practices differed substantially in their assessments of
DCIS histopathology. Among five observers using the same data entry form but their
own system of rating for pathology slides from 53 separate DCIS cases, agreement on
overall diagnosis was only moderate (=0.48). Previous studies that also included two
categories of DCIS (comedo vs. noncomedo or high grade vs. low grade) found similar
results. With only written descriptions of the classification systems, 23 observers rating
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slides from 33 cases resulted in an overall kappa of 0.34 [88], and 23 observers of 107
cases showed slightly higher agreement with an overall kappa of 0.43 [95]. For six
observers rating 125 cases with training that included practice slides and written criteria,
overall kappa was 0.46 [19].
Reliability in the current study was fair for the two component categories used in
most classification systems, pattern of necrosis (=0.35) and maximum nuclear diameter
(=0.22). Within each component, agreement was highest for those category choices
considered most severe, specifically central/comedo-type necrosis and largest nuclear
diameter. Because the most severe categories of each component represent the greatest
cellular change, they are more easily distinguished from normal or benign tissue, and
therefore higher agreement is expected for these categories. In fact, studies comparing
reliability across classification schemes have shown substantially lower kappa scores for
intermediate and low-grade lesions than for those rated as high grade or comedo-type [19,
95].
While a number of histopathologic reliability studies of breast lesions have been
conducted in the past 15 years, this study is the first among published studies to focus on
DCIS cases and specifically on comedo and non-comedo DCIS subtypes. In addition, we
examined the components of diagnosis used by pathologists to delineate between comedo
and non-comedo DCIS subtypes. A previous study that estimated kappa values for
architectural growth patterns and nuclear grade for a small number of DCIS cases
reported a lower inter-observer kappa value for comedo-type growth pattern (=0.38)
and higher values for nuclear grade (high nuclear grade, =0.41, and low nuclear grade,
=0.51) [96]. Pathologists were given specific rating guidelines for the cases, which
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could account for the higher agreement on nuclear grade but does not explain the
difficulty distinguishing comedo-type lesions.
Only one other study examined pathologist reliability for DCIS subtypes and
found slightly lower reliability for comedo versus non-comedo diagnoses compared to
our study (=0.44) [13]. However, the authors examined reliability across all major types
of breast disease, so while more than 180 observers participated, only 17 DCIS cases
were included. The same research group determined reliability among different
classification systems but included only two systems that attempted to distinguish DCIS
subtypes [88].
Other reliability studies compared in situ diagnoses with those of invasive and/or
other proliferative breast diseases and found much higher agreement on overall diagnosis
for DCIS, with kappas ranging from 0.59 to 0.87 [11, 13, 81, 87]. However, distinctions
between carcinoma in situ and benign diseases or invasive carcinomas are much clearer
than those within each disease category. Therefore, better inter-observer reliability is
expected in studies that examine histopathologic agreement differentiating CIS from
proliferative lesions.
Observers in the current study were not required to use a specific rating system.
This allowed for simulation of actual clinical practice and permitted a reliability analysis
of necrosis and nuclear diameter histopathologic components included in the different
classification schemes. In this way, we were able to explore similarities and differences
in methods of classifying comedo versus non-comedo DCIS subtypes. While observers
usually diagnosed comedo-type as having high-grade nuclei and comedo-type necrosis,
less agreement occurred for non-comedo type lesions. DCIS cases that did not have
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severe characteristics of necrosis and nuclear grade seemed to be the hardest to classify.
The implications for clinical decision are that diagnosis and treatment decisions for CIS
may be based upon less than reliable diagnostic criteria.
Pathologists often utilize an ocular micrometer to obtain precise measurements for
maximum nuclear diameter. Observers in this study recorded whether or not they used a
micrometer in their evaluations, but inter-observer agreement for this component was
low, suggesting that differences in the choice of representative nuclei for diameter
measurements may be a source of variation between pathologists. One possibility for the
anomaly is length and amount of experience reading breast cancer slides. All five
pathologists had been in practice for at least 15 years, and three worked at hospitals with
large cancer centers. However, no more detailed information on the pathologists’
training or experience was obtained. Future studies of this type should consider doing so
in order to possibly control for this variable.
Slides from seven of the cases were rated as poor quality by at least three
observers. To assess whether slide quality was associated with agreement, ratings from
those cases were analyzed separately, but agreement among all observers was similar to
those for slides rated as adequate or good quality for any of the categories.
Before a universal classification system for DCIS pathology is developed, a
comprehensive study of actual pathology practices must be conducted to determine where
diagnostic discrepancies occur among pathologists. Future studies could use the same
pathologists and slides to examine reliability without training first, then conduct training
for a particular existing classification system and reassess reliability. The current study
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suggests that one universal system, accompanied by training, is necessary to ensure the
highest possible agreement across pathologists in clinical practice.
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Table 3.1. Frequencies of overall diagnosis by observer, including consensus
DCIS,
comedo-type
DCIS, non-
comedo type
Other* Unable to
Determine
Total
Observer N** (%) N (%) N (%) N (%) N
A 23 (43) 23 (43) 6 (11) 1 (2) 53
B 26 (49) 22 (42) 5 (9) 0 (0) 53
C 27 (51) 19 (36) 7 (13) 0 (0) 53
D 20 (38) 25 (47) 5 (9) 3 (6) 53
E 17 (32) 34 (64) 2 (4) 0 (0) 53
Average*** 22.6 (42.6) 24.6 (46.4) 5 (9.4) 0.8 (1.5) 53
Consensus 24 (45.3) 25 (47.2) 3 (5.7) 1 (1.9) 53
*Includes LCIS, ADH, other in situ proliferation, and no proliferative lesion present
**N=number of slides; percentages may not equal 100 due to rounding
***Average=Total for column ÷ 5
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Table 3.2. Frequencies of pattern of necrosis by observer, including consensus
Central/
comedo-type
Punctate/
individual cell
Absent Unable to
Determine
Total
Observer N* (%) N (%) N (%) N (%) N
A 30 (65) 10 (22) 5 (11) 1 (2) 46
B 33 (69) 3 (6) 11 (23) 1 (2) 48
C 32 (70) 9 (19) 5 (11) 0 (0) 46 
D 26 (59) 2 (4) 15 (33) 2 (4) 45
E 36 (71) 4 (8) 11 (21) 0 (0) 51
Average** 31.4 (66.5) 5.6 (11.9) 9.4 (19.9) 0.8 (1.7) 47.2
Consensus 32 (65.3) 5 (10.2) 7 (14.3) 5 (10.2) 49
*N=number of slides; total number varies by observer and is less than 53 because cases
not diagnosed as DCIS do not have answers for pattern of necrosis.
**Average=Total in column ÷ 5
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Table 3.3. Frequencies of maximum nuclear diameter by observer, including consensus
1.5 to 2
(Small)
2.1 to 2.5
(Medium)
>2.5
(Large)
Unable to determine Total
Observer N** (%) N (%) N (%) N (%) N
A 2 (4) 17 (37) 27 (59) 0 46
B 5 (11) 16 (33) 27 (56) 0 48
C 4 (9) 9 (19) 33 (72) 0 46
D 20 (45) 15 (33) 10 (22) 0 45
E 10 (20) 18 (35) 21 (41) 2 (4) 51
Average*** 8.2 (17.4) 15 (31.8) 23.6 (50.0) 0.4 (0.9) 47.2
Consensus 6 (12.2) 11 (22.5) 27 (55.1) 5 (10.2) 49
NOTE: Maximum nuclear diameter=nuclear diameter of largest red blood cells
**N=number of slides
***Average=Total in column ÷ 5
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Table 3.4. Frequencies of agreement by number of slides for each DCIS component
Frequencies
Overall
Diagnosis
N* (%)
Pattern of
Necrosis
N (%)
Maximum Nuclear
Diameter
N (%)
100% agreement
(5 out of 5
observers)
20 (38) 22 (44) 6 (12)
80% agreement
(4 out of 5
observers)
20 (38) 9 (18) 16 (32)
60% agreement
(3 out of 5
observers)
12 (23) 10 (20) 21 (42)
No majority
agreement
1 (2) 9 (18) 7 (14)
Total 53 50 50
*N=number of cases
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Table 3.5. Mean kappa for each observer versus all other observers and kappa versus
consensus
Component
OBSERVER
Observer vs. All Other
Observers
Mean Kappa* (Range)
Observer vs.
Consensus
Kappa** (95%CI)
Overall Diagnosis
A
B
C
D
E
.55 (.45-.66)
.50 (.34-.65)
.55 (.40-.66)
.39 (.21-.49)
.36 (.21-.48)
.78 (.63, .92)
.74 (.57, .90)
.78 (.63, .92)
.53 (.33, .72)
.55 (.35, .76)
Pattern of Necrosis
A
B
C
D
E
.41 (.27-.50)
.41 (.37-.50)
.37 (.24-.50)
.28 (.23-.37)
.34 (.23-.37)
.65 (.49, .81)
.58 (.41, .75)
.56 (.40, .72)
.30 (.14, .45)
.51 (.31, .71)
Maximum Nuclear Diameter
A
B
C
D
E
.33 (.19-.46)
.30 (.25-.38)
.30 (.21-.46)
.23 (.19-.28)
.28 (.26-.31)
.65 (.49, .81)
.53 (.26, .79)
.53 (.28, .78)
.30 (.12, .48)
.54 (.30, .77)
*Mean kappa = average of all comparisons between that observer and the other four
observers
**Kappa=simple kappa for overall diagnosis and pattern of necrosis, weighted kappa for
maximum nuclear diameter
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Table 3.6. Overall agreement measured by global kappa, all observers combined for each
component and category
DCIS components and
categories
Global Kappa (95% CI)
Overall Diagnosis .48 (.41-.55)
Comedo-type DCIS
Non-comedo type DCIS
Other
.52 (.44-.61)
.43 (.35-.52)
.51 (.43-.60)
Pattern of Necrosis .35 (.30-.41)
Central/comedo-type
Punctate/individual cell
Absent (no necrosis)
.57 (.48-.66)
.18 (.09-.26)
.28 (.19-.37)
Maximum Nuclear Diameter .22 (.16-.28)
1.5 to 2.0
2.1 to 2.5
>2.5
.15 (.07-.24)
.16 (.07-.25)
.33 (.24-.41)
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Figure 3.1. Pattern of necrosis and maximum nuclear diameter combinations for all slides and observers by DCIS subtype
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CHAPTER IV: REPRODUCTIVE AND HORMONAL RISK FACTORS FOR
DUCTAL CARCINOMA IN SITU OF THE BREAST: A COMPARISON WITH
INVASIVE BREAST CANCER
Abstract
Carcinoma in situ (CIS) of the breast now accounts for one-fifth of all newly
diagnosed breast cancer cases. Cases of the most prevalent CIS type, ductal carcinoma in
situ (DCIS), are treated using the same aggressive methods as those for invasive disease,
but recent research indicates some subtypes of DCIS (high grade, or comedo) share
histopathologic and epidemiologic characteristics with invasive disease, while others
(medium or low grade, or non-comedo) show different patterns. Estrogen exposure,
measured by reproductive and hormonal factors, has been associated with invasive breast
cancer (IBC) risk, but its connection with DCIS is less clear.
To investigate whether reproductive and hormonal risk factors differ among
comedo and non-comedo types of DCIS and invasive breast cancer, we used a
population-based case-control study of 1808 invasive and 446 DCIS breast cancer cases
aged 20-74 diagnosed in North Carolina between 1993 and 2001. Controls (N=1564 for
invasive, 458 for DCIS) were frequency-matched to cases by age and race. Odds ratios
(ORs) and 95% confidence intervals (CI) were used to evaluate risk factors for each
subtype of DCIS as well as invasive disease. Two or more full-term pregnancies and
breastfeeding were inversely associated with comedo-type DCIS and invasive breast
cancer (IBC) but showed no effect for non-comedo DCIS. Postmenopausal hormone
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replacement therapy (HRT) use was not associated with either DCIS subtype or IBC.
Increasing duration of OC use was associated with IBC but not associated with DCIS.
Our results support the theory that DCIS is a heterogeneous disease and the etiology of
comedo-type DCIS is more similar to invasive breast cancer than non-comedo DCIS.
Introduction
Carcinoma in situ (CIS) of the breast is a classification for malignant cells that
have not moved beyond the epithelium to invade the basal membrane and is further
categorized as either lobular (LCIS) or ductal (DCIS), depending on its location [97].
DCIS can be classified into comedo (high grade) and non-comedo (medium or low grade)
subtypes based on histopathologic characteristics such as pattern of necrosis and
maximum nuclear diameter. Both biologic and epidemiologic evidence show that some
DCIS develop into invasive disease, but the distinction between those that will and those
representing neoplasms distinct from invasive breast cancer (IBC) is unclear [22, 35, 98-
101].
When the National Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) program began recording incidence rates for DCIS in 1973, the age-
adjusted rate was 2.3 per 100,000 females [38]. By 1992, that figure had jumped to 15.8
per 100,000 [39]. The most dramatic increases have occurred since 1983, with a 17.5%
annual increase in incidence rates between 1983 and 1992 compared to increases of 3.9%
annually from 1973 to 1983 [39]. Separate studies in Detroit [40], Connecticut [41],
Vaud, Switzerland [42], and Florence, Italy [43] have shown that most of this increase
was due to the introduction of screening mammography in the early 1980s and its
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subsequent increasing use in women age 40 and over. However, since 1992 the
proportional change in incidence rates for DCIS has slowed, especially for comedo DCIS
[1]. In addition, 80% of all DCIS diagnosed in the US since 1980 were non-comedo
type.
Whether or not DCIS lesions found through increased detection will progress to
invasive disease is unknown. It is generally believed that comedo-type DCIS is more
similar to invasive disease than is the non-comedo-type. Studies of women with
concomitant DCIS and IBC found higher grade DCIS correlated with higher grade IBC
[102-104]. The same correlation has been observed in long-term follow-up studies of
women with DCIS who developed invasive disease [28, 29, 33]. Autopsy series studies
of women who died from causes other than breast cancer have found prevalence rates of
DCIS ranging from 0.2% to 14.7%, compared with 0-1.8% for invasive breast cancer
[105]. Therefore, some in situ lesions may take much longer to develop invasive traits or
may never become invasive during a woman’s normal lifespan. Because of the
uncertainties regarding DCIS progression, most lesions are treated aggressively.
Knowing which DCIS types are less likely to progress to invasive cancer could lower
morbidity by limiting unnecessary surgical and adjuvant treatment.
Many of the accepted risk factors for invasive breast cancer involve hormonal
exposure, in particular estrogen, whether directly through exogenous use (oral
contraceptives, hormone replacement therapy) or through reproductive events such as
timing of menarche and menopause, pregnancy, and lactation. Previous studies have
found nulliparity, late age at first pregnancy, early menarche, late menopause, no
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lactation, and exogenous hormone use associated with invasive breast cancer [106]. The
connection between estrogen and in situ breast cancer is less clear.
We examined known hormonal and reproductive risk factors for invasive breast
cancer to determine whether they are risk factors for DCIS, and to determine whether risk
factors differ for comedo and non-comedo DCIS subtypes. Odds ratios for DCIS as well
as for DCIS subtypes (comedo, non-comedo) were compared directly with those of
invasive breast cancer in the same North Carolina study population.
Methods
Study Design
The Carolina Breast Cancer Study (CBCS) is a population-based case-control
study of in situ and invasive breast cancer in African-American (AA) and Caucasian
women [74]. Eligible study participants were aged 20 to 74 at time of diagnosis (cases)
or selection (controls) and residing in 24 contiguous counties of eastern and central North
Carolina. Women with first breast cancer diagnoses (in situ or invasive) were identified
through a rapid-ascertainment system in conjunction with the North Carolina Central
Cancer Registry [89], and controls were located via computerized lists from the
Department of Motor Vehicles (under age 65) and the Health Care Finance
Administration (age 65 and over). Controls were frequency-matched to cases on race and
5-year age intervals.
Invasive cases were enrolled in two phases, between 1993 and 1996 (Phase 1) and
from 1996 through 2001 (Phase 2), and were over-sampled for African-Americans and
younger age (20-49 years). Specifically, a process of randomized recruitment using
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predetermined probabilities [75] was used to balance four groups based on age and race:
younger African Americans, older African-Americans, younger non-African Americans,
and older non-African Americans. In order to accomplish this, 100% of African
American cases younger than 50 years, 75% of African American cases at least 50 years
old, 67% of non–African American cases younger than age 50 years, and 20% of non–
African American cases at least 50 years old were sampled [74].
In situ case enrollment occurred between 1996 and 2001 and included pure ductal
carcinoma in situ (DCIS), DCIS with microinvasion to a depth of 2mm, and lobular
carcinoma in situ (LCIS). All in situ cases matching the age and geographic constraints
mentioned above were eligible for the study, with no oversampling on race or age.
Study Population
A total of 705 carcinoma in situ (CIS) cases were identified during the enrollment
period. Seven hundred (99.3%) could be contacted, of which 50 were ineligible or
deceased (7.1%), physicians refused participation for 51 (7.3%), and 58 declined to
participate (8.3%), resulting in a cooperation rate of 83.2% and an overall response rate
of 82.6%. Thirty-eight of the participants completed only a mini questionnaire, which
did not include hormonal or reproductive questions. For the current study, 28 cases of
pure LCIS and 29 cases of DCIS with microinvasion were excluded leaving 446 pure
DCIS cases. Of the 940 controls sampled, 852 were located (90.6%), 122 were ineligible
or deceased (13.0%), and 197 refused participation (21.0%). Cooperation and overall
response rates for controls were 73.0% and 65.2%, respectively. After excluding 75
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women who completed the mini questionnaire only, 458 DCIS study controls remained
for this study.
Risk factor distributions were similar for invasive cancer cases enrolled in both
phases of data collection, so data for all IBC cases from Phase 1 and Phase 2 were
combined for a total of 2704 identified cases. Of those, 2640 (97.6%) were locatable
(contact rate). Two hundred and one were ineligible or deceased (7.4%), physicians
refused participation for 175 (6.5%), and 361 declined to participate (13.4%), resulting in
a cooperation rate of 78.0% and an overall response rate of 76.0%. Ninety-five
completed only the mini questionnaire, leaving 1808 IBC cases for analysis. A total of
3600 controls for IBC cases were identified, of which 2911 were located (80.9%), 427
were ineligible or deceased (11.9%), and 739 declined participation (20.5%). The
cooperation rate for controls was 70.3%, and the overall response rate was 55.0%.
Removal of the 175 who did not complete the full questionnaire left 1564 controls for the
IBC study analyses.
Data Collection
Trained female nurses conducted in-person interviews using a structured
questionnaire. Topics covered by the questionnaire include sociodemographic factors,
menstrual and pregnancy history, medical history, hormone use, family history of cancer,
physical activity and occupational history. The nurse measured height and weight at the
time of the interview; all other questions were answered via self-report. Participants were
given visual aids to assist with recall, such as pictures of common prescription and non-
prescription drugs and calendars to pinpoint dates.
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Statistical Analyses
All statistical analyses were conducted using SAS version 8.2 (SAS Institute Inc.,
Cary, NC, USA). The main outcome variable was ductal carcinoma in situ, which
included all cases of pure DCIS. Initial diagnosis was assigned by the referring physician
and verified by a pathologist employed by the CBCS based on a review of pathology
reports and H&E stained slides. Less than two percent of the cases were reclassified
based on the CBCS pathologist’s evaluation. Main hormonal and reproductive risk
variables included parity (no full-term pregnancies, one, two, three or more), age at first
full-term pregnancy (<26, 26+), lactation (never, ever), oral contraceptive (OC) use
(never, ever) and duration of OC use (<5 years, 5 to 10 years, >10 years), hormone
replacement therapy (HRT) use (never, ever) and duration of HRT use (<5 years, 5-10
years, >10 years), age at menopause (<40, 40-49, 50+), and age at menarche (<11, 12, 13,
14+).
Univariate analyses were used to evaluate exposure and outcome variable
distributions and identify missing values and possible outliers. Participants who
classified their race as American Indian/Eskimo, Asian or Pacific Islander, or Other
(n=13 for DCIS, n=53 for invasive) were combined with Whites, resulting in two race
categories: African-American and non African-American. Age at the time of interview
was computed from self-reported birth date and included in all analyses as a continuous
variable. Women under age 50 were considered postmenopausal if they had undergone
natural menopause (menstruation cessation), bilateral oophorectomy, or irradiation to the
ovaries. In women aged 50 or older, menopausal status was assigned based on
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menstruation cessation. We combined natural and surgical menopause for analysis, since
we were interested in duration of estrogen exposure.
Odds ratios and 95 percent confidence intervals were computed using
unconditional logistic regression. Case-control analyses were conducted for all data in
order to estimate main effects of the risk factors. In addition, case-case analyses were
used to identify factors with different relationships between comedo and non-comedo
DCIS [107]. All regression models contained an offset term to adjust for age and race
frequency matching. Potential effect measure modifiers were identified a priori and
evaluated by comparing models including an interaction term and the main outcome and
exposure effects with models containing the main effects only. These included age
(continuous), race (African American, non-African American), education (less than
college, college or greater), income (<$30,000/year, $30,000+/year), and first-degree
family history of breast cancer (yes, no). Backward elimination with a cut point of
=0.10 determined whether or not the interaction term remained in the final model. In
addition to the main covariates, potential confounders included age, race, education,
income, alcohol use (never, ever), smoking (never, previous, current), first-degree family
history of breast cancer, and body mass index (BMI) (<25 kg/m2, 25-29.9 kg/m2, 30+
kg/m2). If removal of the covariate from the model resulted in a 10 percent or larger
change in stratum-specific regression coefficients, that variable was considered a
confounder and remained in the final model.
All evaluations of potential effect measure modification and confounding were
conducted on the in situ data only, in order to obtain the model with the best fit for that
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data. The resulting model was used for the invasive data in order to make direct
comparisons between in situ and invasive model estimates.
In addition to analyses for all DCIS cases combined, univariate and multivariate
analyses were conducted for DCIS cases stratified on histopathologic subtype (comedo
vs. non-comedo). The study pathologist classified DCIS subtype based on a detailed
microscopic examination of an H&E stained slide for each case. Comedo DCIS was
defined as having comedo-type pattern of necrosis as well as two of the following three
characteristics: large or very large nuclear diameter (>2 times the diameter of a red blood
cell), vesicular nuclear pleomorphism, and prominent nucleoli. All others were
categorized as non-comedo. Fifty-six DCIS cases did not have this examination
performed and were excluded from the subtype analyses, leaving a total of 393 DCIS
cases (163 comedo and 230 non-comedo).
Results
Distributions
Characteristics of both the DCIS and IBC cases and controls are shown in Table
4.1. A total of 904 women participated in the DCIS study, of which 18.1 percent were
African-American (N=164). The mean age of CIS cases (55.16 + 11.07 SD) was slightly
higher than that of controls (54.46 + 10.26 SD), and a higher percentage of CIS cases
than controls were African-American (21.1 vs. 15.3%). A larger proportion of IBC
participants than DCIS subjects, both cases and controls, were African-American because
of over-sampling by race in the IBC study but not in the DCIS portion. IBC cases and
controls were slightly younger than their DCIS counterparts, as reflected in both mean
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and median ages. Participants in the DCIS portion were more likely to be
postmenopausal than those in the IBC group.
Table 4.2 displays reproductive and other characteristics of DCIS study controls
and cases stratified by histopathologic subtype (comedo versus non-comedo). More non-
comedo cases than controls were African-American, and fewer non-comedo cases
reached menopause before age 40 than controls. More comedo cases than non-comedo
cases used oral contraceptives for more than ten years; otherwise, risk factors were
distributed evenly among comedo and non-comedo cases.
Age and race, the only confounders of the associations between cancer outcomes
and hormonal and reproductive risk variables, were included in all multivariate models
along with the offset terms to account for probability sampling by race and age. There
was no significant effect measure modification by any of the evaluated covariates. Final
modeling results for all DCIS and IBC are shown in Table 4.3, and results for comedo
and non-comedo analyses are shown in Table 4.4.
Ductal Carcinoma in Situ Cases vs. Controls and Invasive Cases vs. Controls
Parity was inversely associated with both DCIS and IBC, although the inverse
association increased with number of full-term pregnancies in the DCIS group (p for
trend=0.02) but remained relatively constant for IBC regardless of number of
pregnancies. Ever having breastfed was not associated with DCIS. However, any
lactation was inversely associated with any number of full-term pregnancies in the
invasive cancer group.
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Odds ratios for OC use decreased with increasing duration of use among DCIS
subjects (p for trend=0.05). The opposite was true for invasive cancers: increasing
duration of OC use showed a suggested increasing association with IBC (p for
trend=0.09). HRT use was not associated with DCIS in this study, whereas any HRT use
was inversely associated with invasive disease, especially among long-term users.
Younger age at menopause (<40) and older age at menarche (14+) showed an
inverse association with IBC, and each increase of age at menarche was associated with a
decrease in odds ratio (p for trend=0.001). Older age at menopause (>50) was associated
with invasive disease. There was no association with age at menarche and DCIS but an
inverse association between younger age at menopause (<40) and DCIS.
Ductal Carcinoma in Situ Comedo vs. Non-comedo
Table 4.4 displays odds ratios and 95% confidence intervals for comedo DCIS
cases vs. controls, non-comedo DCIS cases vs. controls, and comedo cases vs. non-
comedo cases (case-case odds ratios). Risk estimates were less precise than for all DCIS
due to fewer numbers of cases when stratified by histology. Any number of full-term
pregnancies was inversely associated with comedo DCIS, with a trend of increasing
inverse association as number of full-term births rose (p for trend=0.02). Non-comedo
DCIS showed an inverse association trend with parity, but ORs were closer to the null.
Ever breastfeeding was inversely associated with comedo DCIS but was not associated
with non-comedo DCIS. Ever use of hormone replacement therapy was inversely
associated with comedo DCIS but not associated with non-comedo DCIS.
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When comedo and non-comedo DCIS cases were compared in a case-case
analysis, duration of oral contraceptive use had a different association with the two DCIS
subtypes. Ten or more years of OC use showed an increased association with comedo
DCIS but an inverse association with non-comedo.
Discussion
Using a large, population-based study of carcinoma in situ of the breast and
invasive breast cancer, we compared known hormonal and reproductive risk factors for
invasive breast cancer in both groups to determine whether they are risk factors for DCIS
as well and to make direct comparisons of odds ratios in the two groups. Parity and
younger age at first full-term pregnancy, and younger age at menopause (<40) were
inversely associated with both DCIS and IBC, while older age at menopause was
positively associated with each. Older age at menarche was inversely associated with
IBC only. Increasing duration of oral contraceptive use showed a trend of increasing
association with IBC. Menopausal status showed no association with either DCIS or
invasive disease.
When DCIS cases in our study were separated into the two main histologic
subtypes, comedo and non-comedo, comedo-type DCIS associations paralleled invasive
results more frequently than non-comedo DCIS. Parity, lactation, and HRT use were
inversely associated with comedo DCIS and IBC but showed no association with non-
comedo DCIS. These results support the theory that DCIS is not a uniform disease and
are in agreement with data showing that comedo DCIS is more likely than non-comedo to
become invasive [108]. Wohlfahrt et al (2004) conducted the only other published study
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to examine reproductive risk factors for comedo and non-comedo DCIS [109]. Their
analyses were limited to parity and age at first full-term birth and found an association
between comedo DCIS and age at first birth of 25 or higher. In contrast, parity showed a
stronger inverse association with comedo DCIS than with non-comedo or all DCIS
combined in our study, especially for two or more full-term pregnancies.
Many studies have examined reproductive risk factors for invasive breast cancer
and DCIS. However, differences in study designs, methods, and populations make
comparisons of results difficult. Including both DCIS and invasive cases from the same
population circumvents many of those issues, allowing for direct comparison between
odds ratios. Eight previous studies of DCIS reproductive or hormonal risk factors have
included invasive cases as well [64-67, 71, 73, 109, 110]. As with our current study,
these eight found few differences in risk factors between DCIS and invasive disease.
Parity [64-67, 71, 73, 109], young age at first full-term pregnancy [65, 67, 71, 73, 109,
110], older age at menarche [65, 67], and higher body mass index [67, 73] were inversely
associated with both outcomes, while older age at menopause and postmenopausal
hormone replacement therapy [65, 73] have been positively associated with both forms of
cancer.
Evidence suggests that a woman’s breasts reach full maturity after a full-term
pregnancy, making the cells less vulnerable to neoplastic changes [58]. In the current
study, ever having a full-term pregnancy was inversely associated with invasive breast
cancer, as was any lactation. For DCIS, the protective association was limited to those
with age at first full-term pregnancy under age 26. Nine previous DCIS risk factor
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studies included parity and age at first full-term pregnancy, all of which found results
similar to ours [64-66, 70-73, 109].
Only three other DCIS studies assessed associations with lactation [64, 66, 73].
Weiss et al and Tretham-Dietz et al found no association between breastfeeding and
either DCIS or IBC, but in the Meeske et al study, lactating for 24 months or more was
associated with DCIS. In the current study, lactation was inversely associated with IBC
but showed no overall association with DCIS. These varied findings may be due to
differences in lactation practices in the underlying populations. For instance,
breastfeeding is more prevalent and done for longer periods of time in China, where a
significant inverse association with lactation for more than 24 months was found for
invasive breast cancer [111]. The predominant practice in Western populations of
breastfeeding for a maximum of one year and often supplementing with formula might
dilute any protective effect in a population such as ours.
Inverse associations between breast cancer and both later age at menarche and
younger age at menopause may be related to length of estrogen exposure. Increase in
estrogen leads to menarche, and decreasing levels precipitate menopause. Estrogen
augmented by progesterone has been shown to promote cell division, which increases the
chance of mutant cell growth [112]. Our results support this theory for both IBC and
DCIS. Increasing age at menarche was inversely associated with IBC in our study, with
the oldest category (age 14+ at menarche) showing the strongest association compared
with the referent category of age 11 or younger at first menses. Compared with women
who experienced menopause during the most common time period, ages 40-49, younger
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age at menopause (<40) was inversely associated with both IBC and DCIS, and older age
at menopause (50 and older) was positively associated with IBC in our study.
Other studies that examined age at menarche and menopause found mixed results.
The studies by Claus et al (2001) and Weiss et al, as well as one involving only
postmenopausal women [70], found no association between age at menarche and DCIS or
invasive disease. Age at menarche of 14+ was protective for premenopausal women with
DCIS and all women with invasive breast cancer in the study by Longnecker et al. Two
studies used the oldest age at menarche group as a referent, and both found an increased
association with invasive disease for the youngest age at menarche group [67, 73].
Menopause at age 55+ was associated with DCIS and IBC in the Longnecker et al study,
and for DCIS only in the study by Claus et al (2001). Age 45+ at menopause showed an
increased association with IBC only in the study by Trentham-Dietz et al. One other
study reported no association between age at menopause and either DCIS or invasive
disease [70].
The link between oral contraceptive use and breast cancer risk is less clear than
with other hormonal risk factors, especially among earlier-stage cancer. OC use showed
no association with DCIS in our study, although there was a trend of increasing
association with increased duration of use for invasive disease. As with IBC, use of oral
contraceptives for more than ten years was associated with comedo DCIS. However,
long-term OC use showed an inverse association with non-comedo DCIS. All other
studies that included both invasive and DCIS cases found OC use was positively
associated with IBC but not associated with DCIS [60, 73, 110, 113, 114].
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Although most other studies found that postmenopausal hormone replacement
therapy was associated with either DCIS or IBC [65, 68-71, 73], HRT was inversely
associated with IBC in our study, especially among those using HRTs for longer than 10
years. While this difference is puzzling, one explanation may be that we did not
differentiate between estrogen-only and estrogen-plus-progestin regimens. Two studies
which did examine HRT (estrogen and progesterone) and ERT (estrogen only) separately
found HRT associated with CIS but not with IBC, while ERT was not associated with
either outcome [65, 68]. A third study found ERT associated with IBC but not with CIS,
and that HRT was not associated with either outcome [69].
Strengths of this study include analyses of both DCIS and invasive data from the
same study, the inclusion of many African-American women, analyses by DCIS
histopathologic subtype, and inclusion of a wide spectrum of reproductive and hormonal
risk factors. Selection bias was a potential issue for this study, since case participants
could have had better and more frequent access to healthcare and therefore
mammography screening. However, we analyzed the data stratified on frequency of
doctor’s visits and having had a mammogram in the two years previous to participation in
the study, and neither affected the odds ratios (data not shown).
For all DCIS combined, our results indicated many similarities between
reproductive and hormonal risk factors for DCIS and invasive breast cancer, in agreement
with previous studies. Separating DCIS into categories according to histopathologic type
showed comedo-type risk factors more closely resembled those of invasive cancer than
risk factors for the non-comedo type did, supporting the theory that higher-grade comedo
DCIS is the most likely type to progress to IBC. In particular, evidence of protective
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effects of some reproductive and hormonal risk factors seen for both DCIS and invasive
disease did not emerge for non-comedo DCIS.
It has already been established that women with non-comedo type DCIS should
be evaluated and treated using criteria different from those of the more aggressive types
of DCIS. Our results support this conclusion, suggesting that the two may be distinct
subtypes with potentially different underlying etiologies. However, future studies will
need to include larger numbers of both DCIS subtypes in order to clarify associations
between each subtype and potential risk factors. With more women being diagnosed at
earlier stages of breast cancer, more precise estimates of these relationships are possible.
62
Table 4.1. Characteristics of ductal carcinoma in situ (DCIS) and invasive cases and
controls
DCIS
Cases
(N=446)
DCIS
Controls
(N=458)
Invasive
Cases
(N=1808)
Invasive
Controls
(N=1564)
Covariate No. % No. % No. % No. %
Age at selection/diagnosis (years)
Mean + SD
Median
Range
55.16+11.07
55
27-74
54.46+10.26
53
27-74
51.01+11.67
49
23-74
51.99+11.47
49
21-74
Race
Non African-American
African-American
352
94
78.9
21.1
388
70
84.7
15.3
1020
788
56.4
43.6
846
718
54.1
45.9
Parity (Number of full-term
pregnancies)
None (nulliparous)
One
Two
Three or more
69
74
159
144
15.5
16.6
35.7
32.3
56
62
175
165
12.2
13.5
38.2
36.0
275
316
557
660
15.2
17.5
30.8
36.5
174
279
496
615
11.1
17.8
31.7
39.3
Age at first full-term pregnancy
Nulliparous
<26 years
26+
Missing
69
250
127
0
15.5
56.1
28.5
0.0
56
105
297
0
12.2
22.9
64.8
0.0
275
521
1005
7
15.2
28.8
55.6
0.4
174
490
897
3
11.1
31.3
57.4
0.2
Lactation
Never
Ever
261
185
58.5
41.5
273
185
59.6
40.4
1174
634
64.9
35.1
950
614
60.7
39.3
Oral contraceptive (OC) use
Never
Ever
Missing
161
382
3
36.1
63.2
0.7
156
300
2
34.1
65.5
0.4
625
1177
6
34.6
65.1
0.3
572
981
11
36.6
62.7
0.7
Age at first OC use
Never
<20
20+
Missing
161
78
202
5
36.1
17.5
45.3
1.1
156
101
198
3
34.1
22.1
43.2
0.7
625
444
730
9
34.6
24.6
40.4
0.5
572
347
632
13
36.6
22.1
40.4
0.8
Duration of OC use
Never
<5 years
5-10 years
>10 years
Missing
161
140
94
48
3
35.1
31.4
21.1
10.8
0.7
156
136
107
57
2
34.1
29.7
23.4
12.4
0.4
625
538
411
228
6
34.6
29.8
22.7
12.6
0.3
572
489
323
169
11
36.6
31.3
20.7
10.8
0.7
Age at menarche
<11
12
13
14+
Missing
98
131
105
111
1
22.0
29.4
23.5
24.9
0.2
87
136
140
95
0
19.0
29.7
30.6
20.7
0.0
405
516
484
401
2
22.4
28.6
26.8
22.2
0.1
306
413
422
415
8
19.7
26.5
27.1
26.7
0.5
Menopausal Status*
Premenopausal
Postmenopausal
142
304
31.8
61.2
153
305
33.4
66.6
873
935
48.3
51.7
718
846
45.9
54.1
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Table 4.1, cont. Characteristics of ductal carcinoma in situ (DCIS) and invasive cases
and controls
DCIS
Cases
(N=446)
DCIS
Controls
(N=458)
Invasive
Cases
(N=1808)
Invasive
Controls
(N=1564)
Covariate No. % No. % No. % No. %
Age at menopause**
<40
40-49
>=50
Missing
47
138
111
8
15.5
45.4
36.5
2.6
67
123
105
10
22.0
40.3
34.4
3.3
185
440
290
20
19.8
47.1
31.0
2.1
213
388
212
33
25.2
45.9
25.1
3.9
Postmenopausal hormone
replacement therapy (HRT) use**
Never
Ever
122
182
40.1
59.9
110
195
36.1
63.9
518
417
55.4
44.6
420
426
49.6
50.4
Duration of HRT use**
Never
<5 years
5-10 years
>10 years
Missing
122
64
60
55
3
40.1
21.1
19.7
18.1
1.0
110
88
50
55
2
36.1
28.9
16.4
18.0
0.7
518
202
115
94
6
55.4
21.6
12.3
10.1
0.6
420
204
98
121
3
49.6
24.1
11.6
14.3
0.4
*Postmenopausal women: <50 years who had undergone natural menopause, bilateral oophorectomy, or
irradiation to the ovaries; age 50+ for whom menstruation had ceased.
**Among postmenopausal women only.
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Table 4.2. Characteristics of reproductive risk factors among comedo and non-comedo
DCIS cases and all DCIS controls
Comedo
DCIS
N=163
Non-comedo
DCIS
N=230
Controls
N=458
Covariate No. % No. % No. %
Age at selection/diagnosis (years)
Mean + SD
Median
Range
55.36 + 11.46
55
27-74
55.56 + 11.11
55
29-74
54.46 + 10.26
53
27-74
Race
Non African-American
African-American
128
35
78.5
21.5
179
51
77.8
22.2
388
70
84.7
15.3
Parity (Number of full-term pregnancies)
None (nulliparous)
One
Two
Three or more
29
27
53
54
17.8
16.6
32.5
33.1
31
43
84
72
13.5
18.7
36.5
31.3
56
62
175
165
12.2
13.5
38.2
36.0
Age at first full-term pregnancy
Nulliparous
<26 years
26+ years
29
94
140
17.8
57.7
24.5
31
129
170
13.5
56.1
30.4
56
110
292
12.2
24.0
63.8
Lactation
Never
Ever
102
61
62.6
37.4
135
95
58.7
41.3
273
185
59.6
40.4
Oral contraceptive (OC) use
Never
Ever
Missing
61
101
1
37.4
62.0
0.6
86
142
2
37.4
61.7
0.9
156
300
2
34.1
65.5
0.4
Age at first OC use
Never
<20
20+
Missing
61
27
73
2
37.4
16.6
44.8
1.2
86
40
101
3
37.4
17.4
43.9
1.3
156
101
198
3
34.1
22.1
43.2
0.7
Duration of OC use
Never
<5 years
5 to 10 years
>10 years
Missing
61
52
26
23
1
37.4
31.9
16.0
14.1
0.6
86
76
52
14
2
37.4
33.0
22.6
6.1
0.9
156
136
107
57
2
34.1
29.7
23.4
12.4
0.4
Age at menarche
<11
12
13
14+
Missing
37
46
37
43
0
22.7
28.2
22.7
26.4
0.0
49
67
54
59
1
21.3
29.1
23.5
25.7
0.4
87
136
140
95
0
19.0
29.7
30.6
20.7
0.0
Menopausal status*
Premenopausal
Postmenopausal
51
112
31.3
68.7
71
159
30.9
69.1
153
305
33.4
66.6
Age at menopause*
<40
40 to 49
50+
Missing
21
48
42
1
18.8
42.9
37.5
0.9
21
79
54
5
13.2
49.7
34.0
3.1
67
123
105
10
22.0
40.3
34.4
3.3
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Table 4.2, cont. Characteristics of reproductive risk factors among comedo and non-
comedo DCIS cases and all DCIS controls
Comedo
DCIS
N=163
Non-comedo
DCIS
N=230
Controls
N=458
Covariate No. % No. % No. %
Postmenopausal HRT use**
Never
Ever
50
62
44.6
55.4
62
97 
 
39.0
61.0
110
195
36.1
63.9
Duration of postmenopausal HRT use**
Never
<5 years
5 to 10 years
>10 years
Missing
50
23
20
19
0
44.6
20.5
17.9
17.0
0.0
62
35
34
25
3
39.0
22.0
21.4
15.7
1.9
110
88
50
55
2
36.1
28.9
16.4
18.0
0.7
NOTE: This table excludes 56 DCIS cases not classified into subtype by the study pathologist.
*Postmenopausal women: <50 years who had undergone natural menopause, bilateral oophorectomy, or
irradiation to the ovaries; age 50+ for whom menstruation had ceased.
**Among postmenopausal women only.
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Table 4.3. Multivariate adjusted odds ratios of reproductive risk factors for ductal
carcinoma in situ and invasive breast cancer
Ductal carcinoma in situ
(DCIS)
Invasive
Variable Cases
N=446
Controls
N=458 OR (95% CI)
Cases
N=1808
Controls
N=1564 OR (95% CI)
Parity (No. of full-
term pregnancies)
None
One
Two
Three or more
69
74
159
144
56
62
175
165
1.00
0.98 (0.60, 1.61)
0.73 (0.48, 1.12)
0.62 (0.40, 0.97)
275
316
557
660
174
279
496
615
1.00
0.76 (0.59, 0.98)
0.78 (0.62, 0.98)
0.79 (0.63, 0.99)
Age at First Full-
Term Pregnancy
Nulliparous
<26 years
26+ years
Missing
69
250
127
0
56
297
105
0
1.00
0.63 (0.42, 0.95)
0.99 (0.64, 1.55)
275
1124
403
7
174
1057
330
3
1.00
0.77 (0.62, 0.95)
0.80 (0.63, 1.03)
Lactation
Never
Ever
261
185
273
185
1.00
1.02 (0.78, 1.34)
1174
634
950
614
1.00
0.77 (0.67, 0.89)
Oral Contraceptive
(OC) Use
Never
Ever
Missing
161
282
3
156
300
2
1.00
1.11 (0.80, 1.53)
625
1177
6
572
981
11
1.00
1.11 (0.94, 1.32)
Age at first OC use
Never
<20
20+
Missing
161
78
202
5
156
101
198
3
1.00
0.74 (0.46, 1.18)
1.18 (0.85, 1.63)
625
444
730
9
572
347
632
13
1.00
1.04 (0.83, 1.31)
1.13 (0.95, 1.34)
Duration of OC Use
Never
<5 years
5 to 10 years
>10 years
Missing
161
140
94
48
3
156
136
107
57
2
1.00
1.21 (0.85, 1.74)
1.03 (0.69, 1.53)
0.95 (0.59, 1.55)
625
538
411
228
6
572
489
323
169
11
1.00
1.06 (0.88, 1.28)
1.15 (0.93, 1.42)
1.21 (0.94, 1.56)
Age at menarche
<11
12
13
14+
Missing
98
131
105
111
1
87
136
140
95
0
1.00
0.85 (0.58, 1.25)
0.66 (0.45, 0.98)
0.98 (0.65, 1.47)
405
516
484
401
2
306
413
422
415
8
1.00
0.95 (0.78, 1.16)
0.86 (0.70, 1.05)
0.72 (0.59, 0.89)
Age at menopause*
<40
40-49
>50
Missing
47
138
111
8
67
123
105
10
0.61 (0.39, 0.95)
1.00
0.89 (0.61, 1.28)
185
440
290
213
388
212
0.68 (0.54, 0.87)
1.00
1.25 (1.00, 1.57)
Postmenopausal
HRT use**
Never
Ever
122
182
110
195
1.00
0.94 (0.66, 1.32)
518
417
420
426
1.00
0.81 (0.66, 0.99)
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Table 4.3, cont. Multivariate adjusted odds ratios of reproductive risk factors for ductal
carcinoma in situ and invasive breast cancer
Ductal carcinoma in situ
(DCIS)
Invasive
Variable Cases
N=446
Controls
N=458 OR (95% CI)
Cases
N=1808
Controls
N=1564 OR (95% CI)
Duration of HRT
use*
Never
<5 years
5-10 years
>10 years
Missing
122
64
60
55
3
110
88
50
55
2
1.00
0.75 (0.49, 1.15)
1.27 (0.79, 2.04)
0.94 (0.59, 1.49)
518
202
115
94
420
204
98
121
1.00
0.80 (0.63, 1.02)
0.99 (0.73, 1.35)
0.67 (0.49, 0.91)
NOTE: All odds ratios adjusted for age, race, and frequency-matching offset terms.
*Among postmenopausal women only.
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Table 4.4. Multivariate-adjusted odds ratios for DCIS reproductive risk factors, stratified by histology
Variable
Comedo
DCIS
N
Non-
comedo
DCIS
N
Controls
N
Comedo vs.
Controls
OR (95% CI)
Non-comedo vs.
Controls
OR (95% CI)
Comedo vs. Non-
comedo
OR (95% CI)
Parity (# of full-term pregnancies)
None (nulliparous)
One
Two
Three or more
29
27
53
54
31
43
84
72
56
62
175
165
1.00
0.81 (0.42, 1.55)
0.57 (0.33, 1.00)
0.53 (0.30, 0.95)
1.00
1.36 (0.74, 2.47)
0.91 (0.54, 1.54)
0.73 (0.42, 1.27)
1.00
0.67 (0.33, 1.35)
0.68 (0.37, 1.25)
0.82 (0.43, 1.54)
Age at first full-term pregnancy
Nulliparous
<26 years
26+ years
29
94
40
31
129
70
56
297
105
1.00
0.55 (0.33, 0.94)
0.71 (0.39, 1.28)
1.00
0.77 (0.47, 1.29)
1.29 (0.74, 2.23)
1.00
0.79 (0.44, 1.42)
0.61 (0.32, 1.16)
Lactation
Never
Ever
102
61
135
95
273
185
1.00
0.82 (0.57, 1.20)
1.00
1.02 (0.72, 1.42)
1.00
0.85 (0.56, 1.29)
Oral Contraceptive (OC) Use
Never
Ever
Missing
61
101
1
86
142
2
156
300
2
1.00
1.08 (0.69, 1.69)
1.00
1.10 (0.75, 1.64)
1.00
1.00 (0.62, 1.59)
Age at first OC use
Never
<20
20+
Missing
61
27
73
2
86
40
101
3
156
101
198
3
1.00
0.67 (0.34, 1.32)
1.14 (0.78, 1.79)
1.00
0.78 (0.44, 1.40)
1.16 (0.78, 1.73)
1.00
0.93 (0.45, 1.92)
1.00 (0.62, 1.62)
Duration of OC use
Never
<5 years
5 to 10 years
>10 years
Missing
61
52
26
23
1
86
76
52
14
2
156
136
107
57
2
1.00
1.21 (0.74, 1.98)
0.78 (0.43, 1.39)
1.31 (0.70, 2.47)
1.00
1.31 (0.85, 2.03)
1.09 (0.67, 1.76)
0.51 (0.25, 1.04)
1.00
0.96 (0.57, 1.62)
0.70 (0.38, 1.31)
2.33 (1.06, 5.09)
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Table 4.4, cont. Multivariate-adjusted odds ratios for DCIS reproductive risk factors, stratified by histology
Variable
Comedo
DCIS
N
Non-
comedo
DCIS
N
Controls
N
Comedo vs.
Controls
OR (95% CI)
Non-comedo vs.
Controls
OR (95% CI)
Comedo vs. Non-
comedo
OR (95% CI)
Age at menarche
<11
12
13
14+
Missing
37
46
37
43
0
49
67
54
59
1
87
136
140
95
0
1.00
0.76 (0.45, 1.28)
0.61 (0.36, 1.04)
1.00 (0.58, 1.71)
1.00
0.88 (0.56, 1.40)
0.66 (0.41, 1.06)
1.01 (0.62, 1.65)
1.00
0.91 (0.51, 1.60)
0.91 (0.50, 1.65)
0.97 (0.54, 1.73)
Age at menopause**
<40
40 to 49
50+
Missing
21
48
42
1
21
79
54
5
67
123
105
10
0.83 (0.46, 1.52)
1.00
0.97 (0.59, 1.59)
0.48 (0.27, 0,84)
1.00
0.75 (0.48, 1.17)
1.67 (0.83, 3.40)
1.00
1.27 (0.27, 2.22)
Postmenopausal hormone replacement therapy
(HRT) use*
Never
Ever
50
62
62
97
110
195
1.00
0.78 (0.49, 1.23)
1.00
1.00 (0.66, 1.52)
1.00
0.77 (0.46, 1.30)
Duration of postmenopausal HRT use*
Never
<5 years
5 to 10 years
>10 years
Missing
50
23
20
19
0
62
35
34
25
3
110
88
50
55
2
1.00
0.66 (0.37, 1.18)
1.03 (0.54, 1.95)
0.78 (0.42, 1.47)
1.00
0.82 (0.49, 1.38)
1.48 (0.84, 2.61)
0.86 (0.48, 1.54)
1.00
0.81 (0.41, 1.58)
0.71 (0.35, 1.43)
0.90 (0.44, 1.87)
NOTE: All odds ratios adjusted for age, race, and frequency-matching offset terms.
*Among postmenopausal women only.
CHAPTER V: CONCLUSIONS
Summary
The studies detailed above contribute additional and necessary information to the
literature regarding histopathology reliability and reproductive and hormonal risk factors
for ductal carcinoma in situ of the breast. Until recently, DCIS was treated as a single
entity. However, strong biological and epidemiological evidence suggests it consists of
at least two subgroups that differ with regard to pathologic characteristics, progression to
invasive disease, and prognosis.
Using the Carolina Breast Cancer Study, DCIS histopathology among practicing
pathologists was examined, with the result that when pathologists ascertain overall
diagnosis by subtype for DCIS, agreement is only moderate in current practice
conditions. Reliability for two common histologic components, comedo and non-
comedo, was fair. In addition, exploring what specific categories of the components
pathologists use to distinguish between comedo and non-comedo subtypes led to the
discovery that the most severe category of each component usually accompanies a
comedo type diagnosis. However, no similar uniformity exists for non-comedo type
tumors.
In the second study, CBCS data was used to divide DCIS cases into comedo and
non-comedo subtypes for risk factor analyses. Specifically, these were reproductive and
hormonal risk factors that contribute to endogenous and exogenous estrogen exposure
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over a woman’s lifetime, which are known risk factors for IBC. Results for comedo
DCIS cases were similar to those for IBC, whereas non-comedo cases showed numerous
differences from either comedo DCIS or IBC. In particular, at least one full-term
pregnancy and any amount of breastfeeding were inversely associated with comedo DCIS
and IBC but showed no association with non-comedo. Long-term OC use showed a
tendency toward increased association with both comedo DCIS and IBC and an inverse
association with non-comedo DCIS, but the estimates were imprecise. These results
support both the cumulative estrogen exposure hypothesis for increased breast cancer risk
and the theory that comedo and non-comedo DCIS may be distinct subtypes.
The most intriguing outcome of this dissertation is that the results of the reliability
study call into question the validity of the case-control study results. If the reliability
rates of comedo and non-comedo DCIS diagnoses found in our reliability study represent
those of clinical practice, the odds ratios in the risk factor study may be wrong.
Specifically, this would result in misclassification of at least a portion of the DCIS
subtypes. Misclassification by subtype was not examined for this dissertation but could
be in the future using the data from the reliability analyses.
Biologic Plausibility
Breast cell growth and development occurs when estrogen binds to and activates
receptors in the cell nucleus [57]. Changes that occur throughout a female’s reproductive
and menopausal stages alter the amount of endogenous estrogen and how it functions. A
current theory suggests that cumulative estrogen exposure increases the chances of
mutant breast cell proliferation, leading to cancer [115].
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Pregnancy and lactation reduce the number of cumulative ovulatory cycles, which
decreases the amount of estrogen exposure. Although estrogen levels are high during
early pregnancy, they decrease as the pregnancy continues and are lowest by 38 weeks
(full-term). An additional theory suggests breast tissue may not reach full maturity until
after a full-term pregnancy, making the cells more resistant to neoplastic changes [58].
The inverse associations between breast cancer and both later age at menarche
and younger age at menopause may be related to length of estrogen exposure. Increase in
estrogen leads to menarche, and decreasing levels precipitate menopause. Both oral
contraceptives and hormone replacement therapy are methods of introducing exogenous
estrogens at different times in a women’s reproductive history. Because each drug
contains distinct regimens of estrogen and progestagens, associations are less clear. A
majority of women on HRT use combined estrogen/progestagen regimens due to risk of
endometrial cancer in women with intact ovaries. Estrogen augmented by progesterone
has been shown to promote cell division, which increases the chance of mutant cell
growth [112]. However, not all progestagens act on estrogen-metabolizing enzymes in
breast cancer cells in the same way, so it is possible that those with less or no metabolic
activity may neutralize estrogenic effects [116].
Public Health Implications
Improvements in ductal carcinoma in situ diagnosis and accurate risk factor
identification for the disease will only help physicians and patients make informed
decisions regarding both prevention and treatment. The results of these analyses support
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previous studies and give additional information that indicates two important areas of
improvement: diagnostic accuracy and further investigation of DCIS subtypes.
Strengths
The Carolina Breast Cancer Study included a large catchment area that was
arranged to maximize data completeness. The population-based design allowed for
generalizability and enabled identification and recruitment of a large number of DCIS
cases and African-American participants, both of which have been lacking in previous
studies. Even without sufficient numbers of African-American women for stratified
analyses, our results can be generalized to at least African-American women from the
study area and arguably to all in North Carolina. Most invasive breast cancer risk factor
studies and nearly all DCIS risk factor studies to date have not achieved such inclusion
because their base populations were predominantly White and/or Hispanic.
The CBCS questionnaire was thorough and included a wide range of potential
exposures and confounders. Because data was collected for invasive and DCIS subjects
in the same manner, we were able to compare DCIS results directly with those for
invasive disease. Visual prompts were used for accuracy during recall of past and present
prescription and non-prescription drug use, and a timeline was used to place past events.
In addition, we were able to combine analyses for parity and lactation as well as age at
first use of oral contraceptives and duration of OC use to determine whether particular
combinations were more likely to affect DCIS or IBC risk.
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Limitations
Statistical analysis for the reliability study was complicated. While the kappa
statistic improves upon percent agreement, using it to compare results among studies
must be done with caution. Knowing prevalence and bias percentages for other studies
makes comparisons more accurate, and these can usually be computed using data
provided. Kappa is not an ideal reliability measure for studies that include multiple raters
and categories such as this; however, no other statistic has been shown to improve upon
it.
Although response rates for IBC and DCIS cases were comparable to those in
previous similar studies, response rates for IBC and DCIS controls were quite a bit lower.
While we do not have information on most of those who did not participate, 10% of the
IBC controls and 16% of the DCIS controls who declined to complete the full interview
answered a mini questionnaire over the phone. The women with and without complete
data were similar on race, parity, education, and age at menarche and menopause.
However, women who completed the full interview were less likely to have used oral
contraceptives or hormone replacement therapy. If these results represent the
characteristics of the other non-participating controls, selection bias would be a factor
and we would have underestimates of the true associations between both breast cancer
types and OC and HRT use.
Recall bias is a potential issue in the case-control study because cases may put
more effort into remembering events they think are related to their diagnosis. The
exposures focused on in our analyses have been mentioned in the media as potentially
associated with breast cancer, so these are the ones most likely to be recalled differently
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between cases and controls. Cases also have the potential to inflate their exposures for
the same reason. If this type of bias exists, the odds ratios would be inflated with respect
to the true risk estimate. As well, older women may have remembered past events with
less accuracy than younger ones. The further a woman is from her reproductive years at
the time of interview, the more chance for error when recalling pregnancy and
breastfeeding events as well as oral contraceptive use and age at menarche. However,
this is equally as likely to occur for cases as controls, so the error would be
nondifferential. In any case, the methods used to trigger accurate memories that were
incorporated into the interview process most likely minimized these errors as much as
can be expected in this type of study.
The possibility always exists that variables not included in the study were
confounders or effect measure modifiers. The bias could be in either direction, causing
an overestimation or underestimation of the true associations. Even though we used an
assortment of variables to represent estrogen exposure, we were unable to measure
estrogen levels metabolically. The variables probably do not represent all estrogen
sources, so conclusions based on estrogenic effect are limited. We did not differentiate
by OC and HRT regimens, so characteristics particular to individual drugs could have
divergent effects that we did not control for. However, each risk factor is important on its
own merit and, when combined, they give an overall picture of how factors related to
estrogen expression link to DCIS risk.
Future Directions
The studies described in this dissertation provide further evidence that DCIS is a
heterogeneous disease that requires a comprehensive agreed-upon classification system
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and should be considered two at least potentially distinct subgroups (comedo and non-
comedo). Our results regarding the heterogeneity of DCIS, when added to those of
previous studies, can encourage pathologists to develop a classification system that can
be validated and replicated and to implement it worldwide as soon as possible. Then,
more complete epidemiologic studies can be carried out to determine differences in risk
factors to address prevention, and clinical trials can elucidate treatment programs tailored
to the subtype.
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APPENDIX: ADDITIONAL TABLES
Table A.1. DCIS Classification Systems
Name and
Categories
Description
Van Nuys Classification [97]
Group 3 (High
grade)
Nuclei with a diameter greater than two red blood cells with
vesicular chromatin and one or more nucleoli; necrosis may be
present or absent; any architectural pattern may be present
Group 2 (Non-high
grade with necrosis)
Any architectural pattern in which central lumina contain
substantial amounts of necrotic neoplastic cells of duct origin;
occasional desquamated or individually apoptotic cells are
ignored; nuclear grade must be intermediate or low
Group 1 (Non-high
grade without
necrosis
Intermediate or low nuclear grade cases without evidence of
intraductal necrotic material
European Pathologists Working Group (EPWG) (aka Holland et al) [97]
Poorly
differentiated
Nuclei: very pleomorphic w/variation in size, irregular;
Chromatin: coarse and clumped
Nucleoli: prominent, mitoses often present; Polarization of
cells: absent or minimal
Central necrosis: usually present, often prominent, individual
cell necrosis usually present
Growth pattern: solid, clinging, pseudomicropapillary or
cribriform; Calcifications: amorphous
Intermediately
differentiated
Nuclei: Mildly pleomorphic cells; some size, outline and
spacing variation; Chromatin: Fine to coarse
Nucleoli: Visible, mitoses occasionally present; Polarization of
cells: Present
Central necrosis: Variable, individual cell necrosis may be
focally present
Growth pattern: Variable; Calcifications: Amorphous or
laminated
Well-differentiated Nuclei: Monomorphic cells, uniform size, regular nuclear
outline & spacing; Chromatin: Uniform, fine
Nucleoli: Insignificant, rare mitoses; Polarization of cells:
Marked
Central necrosis: Absent or minimal, no individual cell necrosis
Growth pattern: Clinging, micropapillary, cribriform or rarely
solid
Calcifications: Psammoma-like or rarely amorphous
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Table A.1. cont, DCIS Classification Systems
Name and
Categories
Description
Nottingham Classification [97]
Pure comedo Central lumina containing necrotic debris surrounded by large
pleomorphic cells in solid masses
DCIS with necrosis
(nonpure comedo)
Central lumina containing necrotic debris, cribriform,
micropapillary, or variable architectural pattern
DCIS without
necrosis
No evidence of intraluminal necrosis, occasional apoptotic
desquamated cells or mucus ignored
Lagios Nuclear Grading System [19]
High Grade (Grade
3)
Nuclear diameter: >2.5-3 times diameter of a red blood cell
(RBC)
Pleomorphism: Prominent
Chromatin pattern: Vesicular
Nucleoli: Often prominent
Mitoses: Frequently demonstrated
Intermediate Grade
(Grade 2)
Nuclear diameter: 2-2.5 times diameter of RBC
Pleomorphism: More uniform
Chromatin pattern: Coarse
Nucleoli: Small
Mitoses: Infrequent
Low Grade (Grade
1)
Nuclear diameter: <2 times diameter of RBC
Pleomorphism: Absent
Chromatin pattern: Diffuse
Nucleoli: Absent
Mitoses: Rare
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Table A.2. Summary of previously published reliability studies for CIS pathology
First Author,
year published
No. of
Raters
No. of
Cases
Categories or Classification System Results*
Rosai J, 1991 5 17 Normal, hyperplasia, atypical
hyperplasia, atypical lobular
hyperplasia, CIS
No cases with 100% agreement, 18% with
80% agreement, 33% with 0% agreement
Schnitt SJ, 1992 6 24 Usual hyperplasia, atypical hyperplasia,
CIS
58% with 100% agreement, 71% with >
83% agreement, 92% with > 67% agreement
Bodian CA, 1993 2 63 Page system for benign breast disease 100% agreement for LCIS cases
Sloane JP, 1994 186-251 72
(17 DCIS)
All CIS
All DCIS
Comedo DCIS
=0.62
=0.23
=0.44
Frierson HF, 1995 6 75 Nottingham modification =0.55
Douglas-Jones
AG, 1996
2 180 Van Nuys
Holland et al
Nottingham
78.9% agreement; 63.8% agreement**
69.5% agreement; 59.2% agreement**
77.8% agreement; 65.6% agreement**
Palli D, 1996 16 81 CIS =0.69
Bethwaite P, 1998 11 25 Van Nuys
Holland et al
=0.66
=0.57
Giardina C, 1998 12 88 CIS =0.64**
Sidawy MK, 1998 6 12 Low nuclear grade DCIS =0.35
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Table A.2., cont. Summary of previously published reliability studies for CIS pathology
First Author,
year published
No. of
Raters
No. of
Cases
Categories or Classification System Results*
Sloane JP, 1998 23 33 Van Nuys
Holland et al
Comedo vs. noncomedo necrosis
High vs. low nuclear grade
=0.42
=0.37
=0.34
=0.46
Wells WA, 1998 26 30 Noninvasive malignant =0.59
Sloane JP, 1999 23 107 All DCIS
High grade DCIS
Intermediate grade DCIS
Low grade DCIS
=0.87
=0.43
=0.17
=0.49
Sneige N, 1999 6 125 Lagios =0.46
Wells WA, 2000 7 40 Van Nuys
Modified Lagios
Holland et al
***=0.26, 0.29, 0.29
***=0.26, 0.57, 0.29
***=0.46, 0.49, 0.53
Ellis IO, 2006 220-466 62 CIS
Comedo DCIS
High grade DCIS
Intermediate grade DCIS
Low grade DCIS
=0.36
=0.45
=0.51
=0.23
=0.31
*Unless otherwise specified, all results are for inter-rater comparisons
**Diagnostic accuracy
***Inter-rater kappa, intra-rater kappa, kappa for diagnostic accuracy
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Table A.3. Summary of CIS Reproductive Risk Factor Studies
First author,
year published
Study design Number of
participants
Major findings
Brinton, 1983 Cross-
sectional
199 CIS Age at first full-term birth 20+ increased risk
Dubin, 1984 Case-control 112 CIS*
2143 controls
Age at first live birth 10-19 yrs. and 2+ children nursed 2+ months
increased risk of CIS
Longnecker, 1996 Case-control 233 CIS
2203 controls
Age at menarche 13+ protective for premenopausal; age at first full-
term pregnancy >20 yrs. increased risk for premenopausal CIS; any
full-term pregnancy protective for postmenopausal
Kerlikowske,
1997
Cross-
sectional
102 DCIS
39,177 controls
Nulliparous or >30 yrs. at first birth increased risk for
postmenopausal
Lambe, 1998 Nested case-
control
1,368 CIS
6837 controls
Any full-term pregnancies protective for CIS; age at first full-term
birth >25 yrs. increased risk for CIS
Gapstur, 1999 Prospective
cohort
175 DCIS
371,477 person-
years of follow-up
Age at first full-term birth >30 yrs. increased risk for DCIS
Trentham-Dietz,
2000
Case-control 238 DCIS, 63 LCIS
3999 controls
2+ full-term pregnancies protective for all CIS; age at first full-term
birth >30 yrs. increased risk for DCIS
Claus, 2001 Case-control 875 DCIS, 123 LCIS
999 controls
Any full-term pregnancy protective for DCIS; age at first live birth
>20 and age at menopause >55 increased risk for DCIS
Meeske, 2004 Case-control 567 CIS
614 controls
3+ full-term pregnancies protective for CIS; lifetime breastfeeding >
24 mos. increased risk for CIS
Wohlfahrt, 2004 Prospective
cohort
694 DCIS, 242 LCIS
22.5 million person-
years of follow-up
4+ full-term births protective for DCIS; age at first birth 25+
increased risk for DCIS and LCIS
*Included cases with <1 cm microinvasion.
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Table A.4. Summary of CIS Hormonal Risk Factor Studies
First author, year
published
Study design Number of participants Major findings
Stanford JL, 1989 Case-control 279 CIS
2183 controls
>5 years OC use decreased risk
Schairer C, 1994 Prospective
cohort
150 CIS
313,902 person-years of
follow-up
Any HRT increased risk; current use of ERT >10 yrs.
increased risk
Brinton LA, 1995 Case-control 227 CIS
1505 controls
No association with OC use
Longnecker MP, 1996 Case-control 233 CIS
2203 controls
Age at menopause 55+ and ever use of ERT or HRT
increased risk for postmenopausal
Henrich JB, 1998 Matched case-
control
32 CIS
160 controls
No association with ERT use
Gapstur SM, 1999 Prospective
cohort
175 DCIS
371,477 person-years of
follow-up
No association with HRT use and DCIS
Trentham-Dietz A,
2000
Case-control 238 DCIS
63 LCIS
3999 controls
Any HRT use increased risk for DCIS; no association
with OC use and DCIS or LCIS
Claus EB, 2003 Case-control 875 DCIS
999 controls
No association with OC use or HRT use
Gill JK, 2006 Case-control 547 CIS
614 controls
No association with OC use
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Table A.5. Reasons for non-participation in CBCS and contact, cooperation, and
response rates for CIS and invasive breast cancer (IBC) cases and controls
CIS
Cases
CIS
Controls
IBC
Cases
IBC
Controls
Total identified for contact 705 940 2704 3600
Not able to locate/non-responsive 5 88 64 689
Ineligible 47 100 165 348
Deceased 3 22 36 79
Physician refused 51 0 175 0
Patient/subject refused 58 197 361 738
Completed mini questionnaire only 38 75 95 182
Completed interview 503 458 1808 1564
Contact rate 99.3% 90.6% 97.5% 80.9%
Cooperation rate 83.2% 73.0% 78.0% 70.3%
Overall response rate 82.6% 65.2% 76.0% 55.0%
NOTE: Invasive cases and controls include phase 1 and phase 2 combined.
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Table A.6. Demographic characteristics of the CBCS participants
DCIS
Cases
N=446
DCIS
Controls
N=458
Invasive
Cases
N=1808
Invasive
Controls
N=1564
N (%) N (%) N (%) N (%)
Race
Non African-American
African-American
352 (78.9)
94 (21.1)
388 (84.7)
70 (15.3)
1020 (56.4)
788 (43.6)
846 (54.1)
718 (45.9)
Age
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
0 (0.0)
2 (0.5)
8 (1.8)
24 (5.4)
53 (11.9)
65 (14.6)
58 (13.0)
61 (13.7)
63 (14.1)
62 (13.9)
50 (11.2)
0 (0.0)
1 (0.2)
4 (0.9)
29 (6.3)
42 (9.2)
82 (17.9)
94 (20.5)
57 (12.5)
56 (12.2)
47 (10.3)
46 (10.0)
6 (0.3)
23 (1.3)
90 (5.0)
176 (9.7)
279 (15.4)
402 (22.2)
171 (9.5)
181 (10.0)
159 (8.8)
178 (9.8)
143 (7.9)
1 (0.1)
10 (0.6)
63 (4.0)
123 (7.9)
250 (16.0)
340 (21.7)
174 (11.1)
162 (10.4)
133 (8.5)
157 (10.0)
151 (9.7)
Education
Less than College
College +
Missing
310 (69.5)
135 (30.3)
1 (0.2)
319 (69.7)
139 (30.3)
0 (0.0)
1300 (71.9)
508 (28.1)
0 (0.0)
1158 (74.1)
405 (25.9)
1 (0.1)
Income
<$15,000
$15,000-$30,000
$30,00-$50,000
>$50,000
Missing
72 (16.1)
81 (18.2)
99 (22.2)
162 (36.3)
32 (7.2)
46 (10.0)
114 (24.9)
101 (22.1)
159 (34.7)
38 (8.3)
404 (22.3)
392 (21.7)
399 (22.1)
484 (26.8)
129 (7.1)
321 (20.5)
322 (20.6)
350 (22.4)
439 (28.1)
132 (8.4)
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